Global Analysis of The Signalling Network of Breast Cancer Cells In Response To Progesterone.

Roni H. G. Wright (✉ roni.wright@crg.es)

Barcelona Institute of Science and Technology (BIST) <https://orcid.org/0000-0002-8194-4614>

Viviana Vastolo

Barcelona Institute of Science and Technology (BIST)

Javier Quilez Oliete

Barcelona Institute of Science and Technology (BIST)

Jose Carbonell-Caballero

Barcelona Institute of Science and Technology (BIST)

Miguel Beato

Barcelona Institute of Science and Technology (BIST)

Research Article

Keywords: Progesterone, breast cancer, chromatin, signal transduction, cell cycle regulation, PARylation, phosphorylation, nuclear structure, kinases, transcription factors

Posted Date: December 15th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-958950/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Global Analysis of the Signalling Network of Breast Cancer Cells in Response to Progesterone.

Roni H. G. Wright ^{1,2*} Viviana Vastolo ¹, Javier Quilez Oliete ¹, José Carbonell-Caballero¹, and Miguel Beato^{1,3*}

¹ Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Dr. Aiguader 88, Barcelona 08003, Spain

² Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.

³ Universitat Pompeu Fabra (UPF), Barcelona, 08003 Spain.

*corresponding authors: roni.wright@crg.eu; miguel.beato@crg.eu

V. Vastolo: Vastolov@gmail.com

J. Quilez Oliete javier.quilez.oliete@gmail.com

J. Carbonell-Caballero jcarbonell.work@gmail.com

Background: Breast cancer cells enter into the cell cycle following progestin exposure by the activation of signalling cascades involving a plethora of enzymes, transcription factors and co-factors that transmit the external signal from the cell membrane to chromatin, ultimately leading to a change of the gene expression program. Although many of the events within the signalling network have been described in isolation, how they globally team up to generate the final cell response is unclear.

Methods: In this study we used antibody microarrays and phosphoproteomics to reveal a dynamic global signalling map that reveals new key regulated proteins and phosphor-sites and links between previously known and novel pathways. T47D breast cancer cells

were used, and phosphosites and pathways highlighted were validated using specific antibodies and phenotypic assays. Bioinformatic analysis revealed an enrichment in novel signalling pathways, a coordinated response between cellular compartments and protein complexes.

Results: Detailed analysis of the data revealed intriguing changes in protein complexes involved in nuclear structure, epithelial to mesenchyme transition (EMT), cell adhesion, as well as transcription factors previously not associated with breast cancer proliferation. Pathway analysis confirmed the key role of MAPK following progesterone and additional hormone regulated phosphosites were identified. Full network analysis shows the activation of new signalling pathways previously not associated with progesterone signalling in breast cancer cells such as ERBB and TRK. As different post-translational modifications can mediate complex crosstalk mechanisms and massive PARylation is also rapidly induced by progestins, we provide details of important chromatin regulatory complexes containing both phosphorylated and PARylated proteins.

Conclusions: This study contributes an important resource for the scientific community, as it identifies novel players and connections meaningful for breast cancer cell biology and potentially relevant for cancer management.

Keywords

Progesterone, breast cancer, chromatin, signal transduction, cell cycle regulation, PARylation, phosphorylation, nuclear structure, kinases, transcription factors

51

52 **Background**

53

54 Female steroid hormones, oestrogen and progesterone play a key role not only in the
55 normal development of target tissues during puberty, pregnancy and menopause but
56 also in breast and endometrium cancer cell proliferation. Breast cancer cells respond to
57 progestin exposure with two intermingled pathways that culminate in extensive gene
58 expression changes and entry in the cell cycle. The classical view is that the hormone
59 diffuses through the cell membrane and binds to intracellular progesterone receptors
60 (PR), which are maintained in an inactive state by a chaperone complex, including Heat
61 Shock Proteins 70 and 90 (HSP70/90). Upon hormone binding, PR weakens its
62 interaction with the chaperones, dimerizes and moves to chromatin where eventually
63 binds to palindromic DNA sequences called progesterone responsive elements (PREs)
64 (Pina et al., 1990). Once bound to chromatin, PR recruits various co-regulators and
65 chromatin remodellers that modulate access for the transcription machinery including
66 RNA polymerase II (Beato et al., 1995).

67 This simplified model was completed later by the finding that a tiny fraction of
68 PR (3-5%) is attached to the cell membrane via palmitoylation at C820 (Migliaccio et
69 al., 1998; Pedram et al., 2007), forming a complex with estrogen receptor alpha (ERα)
70 (Ballare et al., 2003). Upon binding progestins, the membrane anchored PR activates
71 SRC, either directly (Boonyaratanakornkit et al., 2001) or via ERα, initiating a kinase
72 signalling pathway that ends in activation of the extracellular signal-regulated kinase
73 (ERK) (Ballare et al., 2003). ERK1 phosphorylates intracellular PR at S294 favouring
74 its dissociation from the chaperone complex. In the cell nucleus ERK1 activates MSK1
75 (Mitogen-and stress activated protein kinase 1), resulting in the formation of a ternary

complex of PR-ERK1-MSK1, which is the active form of PR able to regulate chromatin structure and gene expression. ERK also activates cyclin dependent kinase 2 (CDK2) that in turns activates ARTD1 (ADP-ribose transferase 1) by phosphorylating two serines in the NAD⁺ binding pocket (Wright et al., 2012). Phosphorylation contributes to dissociation of histone H1 and H2A/H2B dimers (Vicent et al., 2006; Wright et al., 2012) and to local chromatin opening by further recruitment of transcription factors, co-regulators, histone modifiers (PCA, P3000) and ATP-dependent chromatin remodellers (NURF and BAF), ultimately leading to the activation of gene expression changes (Vicent et al., 2011; Vicent et al., 2009a; Vicent et al., 2010). Moreover, there is also evidence for the activation by progesterone of other signaling pathways induced by progesterone, such as AKT (Fu et al., 2010), cAMP (Garg et al., 2017; Takahashi et al., 2009), GSK3 (Rider et al., 2006) and STAT (Hagan et al., 2013). However, many of these studies use different cells of a different types of cells derived from endometrial or ovarian tissues (Lee and Kim, 2014; Wang et al., 2007).

In addition to the key role of the kinase cascades, we have identified a pivotal role for another post-translational modification in progestin induced gene regulation; namely Poly-ADP-ribosylation (PARylation). As discussed above the PAR polymerase PARP1, also known as ADP-ribosyltransferase 1 (ARTD1), is activated within the initial minutes following hormone exposure via phosphorylation by CDK2 (Wright et al., 2012), giving rise to a large increase in PARylation within the cell nucleus (Wright et al., 2012). Parylation of ARTD1 itself and of chromatin proteins is essential for the initial dissociation of histone H1 (Nacht et al., 2016; Vicent et al., 2016). We also found that degradation of PAR to ADP-Ribose by PAR glycohydrolase (PARG) is required for complete chromatin remodelling and activation of the gene expression network (Wright et al., 2016). Mass spec analysis of the proteins interacting with PAR in T47D

cells exposed to progestins revealed structural proteins, DNA damage response proteins and chromatin modifying enzymes (Wright et al., 2016). One key enzyme identified in this study was NUDT5 or NUDIX5 (Nudix hydrolase 5), which hydrolyses ADPR to AMP and ribose-5-phosphate. Subsequently, we found that upon dephosphorylation at T45, NUDT5 can use ADPR and diphosphate for the synthesis of ATP (Wright et al., 2016). In this way, part of the ATP consumed during the synthesis of NAD⁺ and stored in PAR is recovered and used for chromatin remodeling and changes in gene expression. The synthesis of nuclear ATP is transient, peaking at 40 minutes after hormone exposure and returning to basal levels after ~60 min. However, although we know that nuclear ATP synthesis is essential for the initial chromatin remodeling, the role of the nuclear ATP at later time points is unclear. We can envision several hypotheses; as a direct, local source of ATP for the massive amount of ATP-dependent chromatin remodelling and 3D conformational changes induced by hormone (Le Dily et al., 2019; Vicent et al., 2011) or to facilitate phase separation of chromatin fiber (Wright et al., 2019). In any case, we know that nuclear ATP synthesis by NUDT5 is essential for the generation and maintenance of the cancer stem cell population (Pickup et al., 2019).

Over the past years, there has been a large number of studies investigating the role and mechanism of action of one or more of the pathway components in response to progesterone exposure, revealing a dynamic crosstalk between canonical pathways (Boonyaratanakornkit et al., 2008; Faivre et al., 2005; Qiu et al., 2003; Skildum et al., 2005). However, these studies focused on one or very few components at a time, and do not explain how these various pathways interact and coordinate the cell response to hormone. The work described here aims to provide a more comprehensive map of progesterone signalling in breast cancer cells, combining antibody arrays technology,

shotgun proteomics, and previously published PARylation datasets to develop for the first-time a global map of the dynamic signalling events induced by progestins in breast cancer cells.

Methods

Cell culture

The hormone receptor positive breast cancer cell line T47D^M (CLS Cat# 300353/p525_T-47D, RRID:CVCL_0553) was used in all experiments unless otherwise stated. T47D^M cells were routinely grown in RPMI (Supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin (pen/strep), L-glutamine (L-glut) as previously described (Wright et al., 2016). For hormone induction experiments, cells were seeded at a concentration of 5×10^6 per 150mm cell culture dish in RPMI white (15% charcoal stripped FBS, Pen/strep, L-glut) for 48 hours. 16 hours prior to hormone induction (10nM R5020), medium was replaced with RPMI white (0% FBS, Pen/strep, L-glut). Samples were harvested at the time points indicated.

BCA Assay

The total protein content of the samples was calculated prior to antibody array, mass spec or western blotting analysis using BCA assay (Thermo Fisher, catalogue number 23227) according to manufactures instructions.

Protein Visualisation

Changes in phosphorylation sites within individual proteins identified was confirmed by western blotting as previously described (Nacht et al., 2016) using specific antibodies; Progesterone receptor (PGR) phospho-S162 (Abcam Cat# ab58564,

RRID:AB_883089), and as a loading control, total PGR (Santa Cruz Biotechnology Cat# sc-7208, RRID:AB_2164331), total CDK2 (Santa Cruz Biotechnology Cat# sc-6248, RRID:AB_627238) or CDK2 phospho-T160 (Abcam Cat# ab47330, RRID:AB_869087).

Antibody Microarray

Phosphorylation antibody array analysis was carried out by Kinexus™ using Kinexus™ Antibody Microarray (KAM) technology. For each time point 3 biological replicates were prepared independently. For each replicate, 50ug of protein lysate was prepared and samples prepared by Kinexus™ in house (Kinexus Bioinformatics Corporation, RRID:SCR_012553). Signal quantification was performed using ImaGene 8.0 (ImaGene, RRID:SCR_002178) from BioDiscovery (BioDiscovery, RRID:SCR_004557). Background corrected raw intensity data was logarithmically transformed with base 2 and Z scores calculated (Cheadle et al., 2003). Any poor-quality spots based on morphology and/or background, were flagged as unreliable and removed from any subsequent analysis.

Mass Spec Sample Preparation

Sample Digestion	
Amount digested	260 ug
Digestion Buffer	6M Urea/ 200mM ABC
Sonication	No
Reduction	Yes
Reduction agent	DTT
Concentration of reduction agent	100 mM
Reduction buffer	NH ₄ HCO ₃
Time of the reduction (minutes)	60
Temperature of the reduction (°C)	37
Alkylation	Yes
Alkylation reagent	IAM
Concentration of alkylation reagent	200 mM
Alkylation buffer	NH ₄ HCO ₃
Time of the alkylation (minutes)	30
Temperature of the alkylation (°C)	25
Dilution before adding enzyme	No
Enzymes	Lys-C/Tryp
Ratio enzyme-substrate	1/10 + 1/10
Time of digestion	Overnight
Temperature of digestion (°C)	37
Comments	Samples were precipitated O/N with acetone previous to the digestion step in two 130 ug eppendorfs. The pellet was then resuspended in 6M urea 200 mM ABC. Digestion was performed O/N with Lys-C and 8-hour for Tryp.
Date	2016/01/21
Status	Closed

169

170 *Bioinformatic Procedures*

171 Gene Ontology (GO) GO-Biological process (GO-BP), GO-Molecular Process (GO-
172 MF), KEGG (KEGG, RRID:SCR_012773) and Biocarta (BioCarta Pathways,
173 RRID:SCR_006917) pathway analysis of networks was carried out using GeneMania
174 application (GeneMANIA, RRID:SCR_005709) (Warde-Farley et al., 2010) within
175 Cytoscape (Cytoscape, RRID:SCR_003032). Clustering analysis, similarity analysis
176 was carried out using GeneE. Network analysis was performed using Cytoscape v3.5
177 (Shannon et al., 2003). The initial prior knowledge network (PKN) was generated based
178 on known protein-protein interactions only validated experimentally. Significantly
179 enriched pathways were analyzed within the network using CytoKEGG application
180 within Cytoscape. The parent network and each of the individual pathway networks are
181 available for visualization and further analysis using following cytoscape session link
182 found within supplementary materials. Comprehensive resource of mammalian protein
183 complexes (Corum analysis) was carried out using online tool [http://mips.helmholtz-](http://mips.helmholtz-muenchen.de/corum/)
184 [muenchen.de/corum/](http://mips.helmholtz-muenchen.de/corum/) CORUM, RRID:SCR_002254 (Giurgiu et al., 2018). Functional
185 classification GO biological process (BP), molecular function (MF) and cellular
186 component (CC) were carried out using molecular signatures database (MSigD) within

Gene Set Enrichment (GSEA) tool (Gene Set Enrichment Analysis, RRID:SCR_003199) and terms with a p value of less than 0.001 were considered significantly enriched (Liberzon et al., 2011; Subramanian et al., 2005).

Kaplan Meyer and Protein Expression in Clinical Samples

Analysis of the overall survival of breast cancer patients using a Kaplan-Meier plot were carried out using KMPlotter (Gyorffy et al., 2010), <https://kmplot.com/analysis/> n=3951. All patients' samples were included in the analysis shown, i.e ER, PR status, subtype, lymph node status and grade. Analysis of protein expression levels in breast tumour versus normal samples were representative of those within the Human Protein Atlas database (Uhlen et al., 2015) <http://www.proteinatlas.org>.

Results

1. Prior Knowledge Network

Before starting to add quantitative dynamic data to the already existing knowledge of progesterone signalling events in breast cancer cells, we have generated a “prior knowledge network (PKN)”, based on the published literature (Fig.S1A-B, and Supplementary material; Cytoscape Session 1). Each protein-protein interaction is characterized based on type (interaction, phosphorylation or dissociation) and is displayed as a unique edge. The corresponding literature is given in Fig. S1B and within the Cytoscape session. The PKN already shows the key role played by kinases in the response of breast cancer cells to progestins. First, progestins via ERα activate SRC1 that phosphorylates MAPKK1, that activates ERK1, that phosphorylates PGR,

resulting in dissociation from the HSP90A and B proteins (Haverinen et al., 2001; Smith, 1993). Activated ERK1 also phosphorylates ERa at S118 (Kato et al., 1995). ERK1 in association with hormone receptors translocates to the cell nucleus where it phosphorylates MSK1 (Reyes et al 2016), leading to the formation of an active complex PR-ERK-MSK1 that interacts with chromatin containing accessible PRE. Activated PR also interacts with PLK1 that activates MLL2 (Wierer et al., 2013), with CDK2 that phosphorylates and activates ARTD1 (Wright et al., 2012), and with JAK2 that activates STAT5 (Hagan et al., 2013). Simultaneously, membrane activated SRC1, also activate RAS and EGFR (Boonyaratanakornkit et al., 2007), which feeds back activating the MAPK cascade. Membrane associated ERa also activates PI3K and cAMP, which upon binding with AKT and PKA respectively lead to the activation (via interaction and direct phosphorylation) of GSK3, mTOR (Ciruelos Gil, 2014; Ortega et al., 2020) and the arginine methyltransferases CARM1 and PRMT1 within the nucleus (Lange, 2008; Li et al., 2003; Malbeteau et al., 2020). This brief description of the PKN shows that it already encompasses a great degree of complexity and complementary connection that need additional data to be resolved.

2. Microarrays of antibodies to phosphorylated sites in proteins

Our plan was to combine antibody microarray technology and shotgun phosphoproteomics in T47D^M breast cancer cells exposed to 10 nM R5020 for different lengths of time, as previously described (Wright et al., 2012). For each experimental approach and exposure time total protein extracts were harvested in triplicate. For the antibody arrays, data was collected, filtered for quality control and summarized as log₂ ratio over time zero (as described in materials and methods, Fig. S2A). This dataset provided 246 unique phosphorylation sites corresponding to 155 proteins (Fig. 1A,

Supplementary Table S1). The majority of proteins contain 1 phosphorylation site, although for several proteins (Tau, RB1, MAP2K1, PTK2 and the protein kinase RPS6KA1) 7 or more significantly regulated phosphorylation sites were identified (Fig. S2B).

Analysis of the number of phosphorylation sites clearly showed a rapid activation already 1-minute following hormone (68 significant phosphorylation events Fig 1B). Signalling persists throughout the time course showing two peaks at 30- and 360-minutes following hormone (Fig. 1B). Phosphorylation sites were characterized as up or down-regulated, using a threshold for the $\log_2$ fold change with respect to time 0 of $-0.6 <$ or > 0.6 respectively (Fig 1C). We see a trend for early phosphorylation sites to be dynamically increased compared to time zero, in contrast to later time points where protein phosphorylation sites as a whole decrease compared to time zero (Fig 1C). The majority of phosphorylation sites identified belong to protein kinases (45%), co-factors (11%), transcription factors (18%) and structural proteins (13%). (Fig 1D). Combining the identified phosphorylation sites over the time course reveals that the majority of sites are regulated at more than one time point (Fig 1E), however the protein function enrichment does not alter significantly over time, with kinases and transcription factors being the main protein groups where the phosphorylation sites are observed (Fig. S2C).

Pathway and gene ontology (GO) for biological function (BP) molecular function (MF) analysis revealed a significant increase in Cancer pathways (Fig S2D), signal transduction, biopolymer metabolic process and kinase activity (Fig 2SE and F). Within this dataset we observed a strongly upregulated phosphorylation of the MAPK Signal-Integrating Kinase 1, MNK1 at T250/T255 (Fig. 1F) in T47D in response to progesterone stimulation. Phosphorylation of MNK1 at T250/T255 by ERK induces

the activity of MNK1 (Dolniak et al., 2008). Once activated, MNK1 phosphorylates its targets, including the proto-oncogene Eukaryotic Translation Initiation Factor 4E (EIF4E), for which we also observed a modest phosphorylation which follows a similar pattern to MNK1 (Fig. 1F). Activation of MNK1 has been shown to promote cell proliferation thus MNK1 inhibitors appear as an exciting opportunity for cancer therapy. MNK1 signalling play a key role in invasive breast cancer growth (Guo et al., 2019), MNK1 inhibitors have been shown to block breast cancer proliferation in multiple cell lines (Wheater et al., 2010), and its downstream target EIF4E is overexpressed in tumour versus normal samples from breast cancer patients (Fig. 1G) and associated with a poor overall survival (Fig. 1H). Our results are the first indication that MNK1 activation may be relevant for progesterone induced breast cancer cell proliferation.

We found that CDK2 plays an important role in progesterone signaling, activating ARTD1, and phosphorylating histone H1 (Wright et al., 2012). CDK2 activity is controlled by the formation of an active complex with the cyclin partner; either Cyclin E or A. In addition to binding the cyclin partner, CDKs are also controlled via interactions with Kinase Inhibitory Proteins (KIPs). p27/KIP is rapidly dephosphorylated at T187 in response to hormone, dropping sharply at 1 minute after hormone exposure (Fig. 1J), when CDK2 is phosphorylated and activated. Phosphorylation of p27 at T187 results in the proteins ubiquitination and degradation and inhibits the interaction with CDK2 (Grimmler et al., 2007), which would result in the release of CDK2 from the inhibitory protein resulting in the activation of ARTD1 and subsequent nuclear effects. In addition, we observe the coordinated activation of the upstream kinase of CDK2 at T160; ERK at Y202/204 (Fig. 1K) and could validate the phosphorylation of CDK2 T160 via ERK by western blotting in the presence of

ERK inhibition (Fig. 1L). CDK2 at T160 is the active phosphorylation site of CDK2 peaking at 1-minute following hormone exposure (Fig. 1K) in contrast to the inactive phosphorylation site of CDK2 (T14/Y15) which peaks at 60 minutes following hormone exposure to silence the kinase (Fig. 1M). The activity of the phosphatase CDC25C is key for the removal of the inhibitory T14/Y15 phosphorylation sites of CDK2. The phosphatase itself is inactivated by phosphorylation at S216. We observe a peak in CDC25C phosphorylation prior to and following 60 minutes of hormone exposure, which would permit the phosphorylation of the inhibitory phosphorylation site in CDK2 (Fig. 1M and N). Going one step further; MAPKAPK2, the kinase which phosphorylates CDC25C at S216 is activated following the same time dynamic as its target (Fig. 1O). Although the importance of CDK2 in progestin induced cell proliferation has been studied (Trevino et al., 2016; Wright et al., 2012) the complex mechanism of CDK2 activation; phosphorylation of active/inactive marks, activation and regulation of upstream phosphatases and kinases was not clear until now (Fig. 1P). These examples of the dynamic phosphorylation of MNK1 and CDK2 highlight the insight that can be gained by this type of global signaling datasets.

3. Shotgun phosphoproteomics

To complement the microarray dataset, we performed shotgun phosphoproteomic analysis using mass spec. Phospho-peptides from T47D^M cells exposed to 10 nM R5020 for the same duration as in the array experiments, were enriched using TiO₂ and phosphorylated peptides identified by LC-MS-MS (Fig. 2A, Fig. S3A, Supplementary Table S1). We identified changes in 310 unique phosphorylation sites within 264 unique proteins (Fig 2B and C). The majority of proteins exhibited regulation of a single phosphosite, except for the serine/arginine repetitive matrix protein, SRRM1, involved

in mRNA processing and the TP53 enhancing protein TP53BP1, that exhibited 8 and 10 regulated phosphorylation sites respectively (Fig. S3B). Most phosphorylation sites identified were phosphor-serine consistent with the biological ratio of residue specific phosphorylation (Fig 2D). Over the time course, changes at each time point were identified as either up ($\log_2FC > 0.6$) or down ($\log_2FC < -0.6$) regulated (Fig. 2E). Up-regulated sites prevailed at early time points and many of these phosphorylation sites were significantly regulated at more than one time point (Fig. 2F). Pathway and GO-BP (Biological Process) and MF (Molecular Function) enrichment analysis was consistent with the antibody array enrichment and revealed an increase in pathways in cancer, biopolymer metabolic process and kinase activity (Fig. S3C-E).

PR S294 is rapidly phosphorylated in response to hormone resulting in its activation and dissociation from chaperone complexes and increase protein turnover (Lange et al., 2000). In recent years it has been shown that clinical samples assigned as “PR low” actually have elevated levels of phosphorylated PR S294 and that this phosphorylation is associated with a genetic signature linked to cancer stem cell growth and increased recurrence which may have implications for the treatment of PR low patients with anti-progestins (Knutson et al., 2017). Phosphorylation of PR S162 in the hinge region showed a strong hormone induced increase by mass spec (Fig. 2G and H). Phosphorylation within this region of PGR has been previously reported to be mediated by CDK2 (Knotts et al., 2001), which we were able to confirm as the specific phosphorylation of S162 PR in response to progesterone was strongly decreased in the presence of CDK2 inhibition (Fig. 2H).

4. Functional Analysis

In order to investigate the dynamics of progestin signalling over time and with the aim of avoiding inherent biases generated from either technical approach, we combined the significantly regulated phosphorylation sites from both datasets (Fig. 1 and 2) resulting in a list of 420 unique phosphorylation sites within 390 proteins (Fig. S4A). PCA analysis of the samples reveals a clear separation of the phosphorylation data at 6 hours following hormone, given the majority of phosphorylation sites are rapid effect this separation of the latest time point may reveal changes in protein levels at this time point. The majority of these proteins showed the regulation of a single phosphorylation event with the exception of several highlighted proteins, including FAK, MAPT and EGFR (Fig. S4C). As in the individual analysis, phosphorylation sites were significantly regulated over several time points (Fig. S4D) and showed a switch from up-regulated sites early after hormone exposure to down-regulated sites at later time points (Fig. S4D). KEGG pathway analysis shows a significant enrichment in MAPK, PI3K-AKT, neurotrophin (TRK) and ERBB signalling pathways (Fig. 3A, Supplementary Table S2), in addition to pathways key in the progression of cancer, specifically cancer stem cells, such as focal adhesion (Fig. 3A).

GO cellular component analysis reveals a dynamic pattern of specific cellular compartments over time (Fig. 3B, Supplementary Table S3). As expected, over the whole-time course, proteins are mainly found within the cytosol and nucleoplasm. However, prior to hormone exposure, phosphorylated proteins are enriched in RNA transcription repression complex and nuclear chromatin. The addition of hormone rapidly induces the phosphorylation of the membrane rafts, components of focal adhesion and protein kinases consistent with published works whereby signalling initiates from the plasma membrane. This transient phosphorylation of the membrane rafts diminish after 1 minute and is followed by the phosphorylation of transcription

factors and proteins within the cytoskeleton (Fig. 3B). Interestingly, in line with our findings showing the generation of nuclear ATP synthesis independent of mitochondrial supplementation at 30 minutes after hormone we observe an enrichment in phosphorylated proteins located within the mitochondrial membrane at 15 minutes (Fig. 3B). The dynamic regulation of these proteins; CYB5B (cytochrome b5), the transcriptional activator ATF2 (Cyclic AMP-dependent transcription factor ATF-2), RPS6KB1 (Ribosomal protein S6 kinase beta-1) and PI4KB (Phosphatidylinositol 4-kinase beta) (Fig. S4F) may suggest an as yet undiscovered crosstalk between the nuclear and mitochondrial ATP synthesis pathways. Mitochondrial PR (PR-M) is a truncated isoform of the nuclear progesterone receptors PRB and PRA, which lacks the N-terminal DNA binding domain present in PRA and PRB but does contain the hinge region responsible for dimerization and the ligand binding domain (Price and Dai, 2015). PR-M has been shown to increase cellular respiration hence cell energy levels in response to ligand in various physiological situations and animal models (Dai et al., 2019). Therefore, the coordinated phosphorylation of proteins within the mitochondria in response to ligand (Fig. S4F) in breast cancer cells may provide an interesting insight into a possible crosstalk between mitochondrial PR-M and the nuclear receptors PRA and PRB.

At 60 minutes following hormone exposure the main localization of phosphorylation changes and shifts again to nuclear matrix proteins and proteins found within distinct regions of the nucleus, such as PML bodies (Fig. 3B group IV), which may be involved in the reorganization of chromatin in response to progestins (Le Dily et al., 2019). At 6 hours following hormone exposure cells enter the early stages of entering the cell cycle and movement is increased. This is also evident by the

enrichment of phosphorylation sites in proteins within cell-cell junctions, the cytoskeleton and microtubules (Fig. 3B group V).

5. Protein class analysis

The majority of identified phosphorylated proteins (60%) were assigned to one class, however due to the promiscuous nature of enzymes nearly 40% were assigned to more than one class (Fig. S4G). Taking first only the parent class into account, we observed 5 distinct functions; 1) nucleic acid binding, 2) enzymes, 3) structural proteins, 4) protein modulators, and 5) proteins involved in signalling, membrane and cell-cell contacts (Fig. S4H). Each function class consists of sub-groups (Fig. S5A-F). The Nucleic Acid binding class includes DNA binding proteins, helicases, nucleases and RNA binding protein subgroups (Fig. S5A). The enzyme class is dominated by kinases but also includes histone modifying enzymes, hydrolases, ligases and oxidoreductases (Fig. S5D). The structural class is dominated by cytoskeleton proteins (Fig. S5F). The protein modulator class includes chaperones and various kinases and G proteins regulators (Fig. S5C). The cell signalling and the membrane/cell-cell contact classes are more complex and include many specialized proteins such as signalling molecules, receptors and transporters (Fig. S5B and E).

Gene Ontology of Biological Processes (GO-BP) and Molecular Function (GO-MF) showed an enrichment in signal transduction and general biological processes across the entire time course (Fig. S6A and B, Supplementary Tables S4 and S5). However, several interesting dynamic functions were identified. For instance, transcription co-factors, transcriptional repressors and transcription factor binding were already enriched 1 minute after hormone exposure (Fig. S6B) consistent with our previous

observations of rapid transcription factor recruitment following hormone exposure (Nacht et al., 2016; Vicent et al., 2011). We observed enrichment in ATP binding and Adenyl-ribonucleotide binding after 5 and 60 min of hormone exposure (Fig. S6B), which may represent regulation of the two cycles of ATP dependent chromatin modifiers in response to progesterone (Vicent et al., 2009b; Wright et al., 2016). KEGG pathway analysis reveals a significant enrichment in signalling and in many cancer pathways, including Prostate, Glioma, CML, lung, AML, endometrial and pancreatic cancer, as well as focal adhesion and tight junctions (Fig. S6C). Annotated signalling cascades were significantly enriched at all time points in response to progestin, including MAPK, neurotrophin (TRK), ERBB, FC-receptor and insulin signalling (Fig. S6C).

6. *Specific pathways: Roles of AMPK, insulin TNFa, and PIK3*

K Means clustering analysis revealed six patterns of regulation over the time course (Fig. 3C). Similarity analysis of all phosphorylation sites within all clusters shows several interesting dynamics. First, “Early-risers” cluster 1 and 4, are positively correlated on the similarity matrix and show their initial increase in phosphorylation early at 1 and 5 minutes, respectively (Fig. 3D). GO-BP analysis of the proteins contained within these clusters shows an enrichment in signal regulation, and signalling cascades including Hippo, NFk-B and MAPK pathways (Fig. 3E, Supplementary Table S9). Second, clusters 3 and 6 show an opposing nature (negative correlation Fig. 3D). This antagonistic behavior of the two clusters is clearly shown averaging the signal of all phosphorylation within each cluster (Fig. 3F). Corum (comprehensive resource of mammalian protein complexes) analysis of the significantly enriched protein complexes contained within clusters 3 and 6 (Supplementary Table S6) showed that

most protein complexes were enriched in one cluster or the other (Fig. 3G), likely representing crosstalk. Ten protein complexes were found to be enriched in both cluster 3 and 6, having phosphorylation sites within the same protein complex regulated in an opposite manner (Fig. 3G).

One such complex was the cMyc-ATPase-Helicase complex, which contains 5 proteins; cMyc, the chromatin remodeling component BAF53, the ATP-dependent helicases RUVBL1 and 2 (also known as TIP48 and 49) and the histone acetyltransferase, TRRAP. This complex is involved in chromatin organization, histone acetylation and transcriptional regulation (Park et al., 2002). Analysis of the phosphorylation sites showed that two sites (S373, T58) within Myc were increased early after hormone exposure, and decreased after 60 minutes, whereas one site of BAF53 (S233) shows the opposite dynamic (Fig. 3H). Database analysis also reveals a strong overexpression of BAF53 in tumour versus normal samples in multiple cancer types (Fig. 3I). Myc has an important role in breast cancer growth via the activation of AMPK (von Eyss et al., 2015).

The AMP-activated protein kinase (AMPK), exhibited a decrease in T183 phosphorylation in response to hormone. This site is phosphorylated by CAMKK1 or 2 (Hurley et al., 2005). AMPK is a master sensor, and its activation inhibits several kinase pathways including mTOR, NfκB, JAK/STAT, insulin and Hippo (Hadad et al., 2008; Montero et al., 2014; Yamaguchi and Taouk, 2020; Zhao et al., 2017). In addition, active AMPK inhibits the phosphorylation of PR S294, PR recruitment to chromatin and the activation of progesterone regulated genes (Wu et al., 2011). Activation of the kinase, specifically requires the phosphorylation of AMPK at T183 by CAMKKs, and de-phosphorylation of this site has been shown to be induced by estrogens and androgens in adipocytes (McInnes et al., 2012; McInnes et al., 2006).

460 Previous published results and the data presented here suggests a model where AMPK
461 must be silenced in order for regulatory pathways described and PR itself to be active,
462 which is what we observe within 1 minute of progesterone stimulation (Fig. 3J and K).

463 Further in-depth analysis of the complexes which are regulated by
464 phosphorylation in response to progestin revealed a full list of complexes with at least
465 2 proteins phosphorylated in response to hormone. One of them is the Sam68-p85
466 PI3K-IRS-1-IR signalling complex, which encompasses the insulin receptor (INSR),
467 the insulin receptor substrate 1 (IRS1), the KH domain containing transduction-
468 associated protein 1 (Sam68) and the phosphatidylinositol 3-kinase regulatory subunit
469 alpha (GRB1). This protein complex is involved in insulin signalling and has been
470 proposed to provide a link between the PI3K pathway and other signalling cascades of
471 insulin or p21/RAS (Sanchez-Margalet and Najib, 2001). We observed a dynamic
472 phosphorylation of several sites within the complex (Fig. 4A), including 4 distinct
473 phosphorylation events within IRS1, two of which peak at 1 minute (S312, S639) and
474 two sites where the peak in phosphorylation is observed at 60 minutes (Y1179, and
475 Y612). S312 has been shown to be directly phosphorylated by c-Jun N-terminal kinase
476 (JNK1) in breast cancer signalling (Mamay et al., 2003) and this phosphorylation
477 inhibits its interaction with IKKA. S639 is phosphorylated by mTOR has been linked
478 to PI3K/Akt/mTOR signalling in breast cancer (Eto, 2010; Tzatsos, 2009) and effects
479 the intracellular localization of IRS1 (Hiratani et al., 2005). Y1179 has been reported
480 to be phosphorylated by IGF1R or INSR itself (Xu et al., 1995) and Y612
481 phosphorylation activates the interaction with PIK3R1 (Valverde et al., 2003).

482 The phosphorylation of several components of the TNFa/NFkB signalling
483 complex were also identified (Fig. 4B). This complex is involved in I-kB kinase/NF-
484 kB signalling in tumour progression. Indeed, complex components IKK α , RelB and

p52 are associated with decreased cancer-specific survival in ERa-positive breast cancer (Paul et al., 2018). This may be linked to the cancer stem cell niche, which we showed recently was present in T47D cells grown in 3D cultures (Pickup et al., 2019). NFkB regulates self-renewal in breast cancer stem cell (BCSC) models and deletion of IKK α in mammary-gland epithelial cells affects progestin-driven breast cancer (Schramek et al., 2010; Shostak and Chariot, 2011). Indeed, the upstream activator RANK ligand (RANKL) and hence the RANK pathway promotes mammary tumor formation, (Gonzalez-Suarez et al., 2010), (Schramek et al., 2010). Another example is the P130Cas-ER-cSrc-PIK3 kinase complex (Fig. 4C). Which has been shown to induce transcriptional changes in response to estrogen and mammary proliferation in breast cancer. The authors showed that estradiol triggers the association of ERa, c-Src, the p85 subunit of PI 3-kinase (PI3K) and p130Cas in a macromolecular complex and activates the c-Src kinase leading to p130Cas-dependent Erk1/2 phosphorylation (Cabodi et al., 2004; Cabodi et al., 2006). Given the similarity of the phosphorylation dynamics, peaking early at 5 and 15 minutes across Src, PIK3 and ESR1 within the complex induced by progestin (Fig. 4C right panel) this may (similarly to the induction by estrogen shown by others) present a novel ERa-ERK-cSrc activation mechanism in response to progestin in breast cancer cells.

7. Crosstalk between Progestin induced Phosphorylation and PARylation

Recently, it has been shown that the majority of PARylation events on eukaryotic nuclear proteins take place on serine residues rather than acidic residues as previously accepted (Bonfiglio et al., 2017a; Bonfiglio et al., 2017b; Leidecker et al., 2016; Liu et al., 2017; Martello et al., 2016; Messner et al., 2010). Given the enrichment of serine

in the phosphorylation dataset (Fig. 2D) and the importance of both PTMs in progestin gene regulation (Wright et al., 2016), we investigated the overlap between PARylation sites and phosphorylation sites within protein complexes. We identified 52 proteins, which were both phosphorylated and PARylated in response to progestins in breast cancer cells (Fig. 4D). Cellular component analysis of this set of 52 proteins indicates a significant enrichment in nuclear, cytoskeleton and chromatin contained proteins (Fig. 4E, Supplementary Table S7), in line with the well described role of PAR in the nucleus, nuclear organization, chromatin organization, relaxation and transcriptional regulation (Hassa et al., 2006; Hoch and Polo, 2019; Leung, 2014; Thomas and Tulin, 2013). This finding may indicate a crosstalk between PARylation and phosphorylation with regards to nuclear structure and chromatin organization. Analysis of complexes significantly enriched within this group of proteins revealed 12 protein complexes (Supplementary Table S8), which contained proteins both PARylated and phosphorylated. One of them is the KSR1-RAF1-MEK complex composed of MEK1 and 2, both PARylated and phosphorylated, and RAF1 which is phosphorylated (Fig. 4F). This complex is involved in the MAPK cascade, and in response to EGF it activates BRAF mediated phosphorylation of MEK1, at 3 sites, and MEK2, which activate MAPK1 and 3 (McKay et al., 2009). In our dataset we observe a clear change in phosphorylation of all members of the complex in response to progestin (Fig. 4F right panel).

We also observed the phosphorylation and PARylation of the Emerin complex (Fig. 4G). This complex is involved in DNA replication, transcription and structural integrity of the nucleus, specifically of the inner nuclear membrane (Holaska and Wilson, 2007). Depletion of Emerin results in changes in the organisation and dynamics of the nucleus, increased chromatin mobility and a mis-localisation of chromosome

territories (Ranade et al., 2019). Within this complex we find proteins phosphorylated, PARylated, or phosphorylated and PARylated (Fig. 4G). Given the role of PAR in the structure of the nucleus, this complex may present an interesting example for studying the PARylation, phosphorylation crosstalk.

As discussed, prior to hormone exposure PR is present in an inactive complex with the HSP70 and 90 proteins as part of the Kinase Maturation Complex. We know that progestins promote the phosphorylation and dimerization of the receptor and we found that phosphorylation of the HSP90 and 70, along with other members of the complex, is initiated within 1 minute of hormone exposure (Fig. 4H), again showing a rapid and concerted phosphorylation of several members of the complex (Fig. 4H). In addition, the HSPs are also PARylated as compared to other components where only phosphorylation (MARK2, MAP2K5) or PARylation (14-3-3 components) are present (Fig. 4I and J). Further investigation regarding the crosstalk between PARylation and phosphorylation within protein complexes will be the focus of future studies.

8. Progesterone Signalling Network Generation

In order to understand the crosstalk between the signalling pathways activated by Progesterone in breast cancer cells, a Protein-Protein Interaction (PPI) network was generated using all identified phosphorylation sites (Supp. File: Network session 2), based on known PPI (evidence based). The resulting network consists of 427 nodes (proteins) and 4309 unique interactions (edges) (Fig S7A). Pathway analysis was carried out on this network, using GenemaniaTM, and 23 statistically significant ($p < 0.01$) pathways were identified (Supplementary Table S9 and S10). The proteins and interactions (nodes and edges) associated with each pathway were selected and new

networks generated (Supp. File: Network session 2). Several of which are shown in Fig. S7B-G and discussed briefly below.

One such pathway, the Fc receptor signalling pathway was identified as enriched (Fig. S6C) and the PPI network is shown in Fig. S7B. Fc receptors are cell surface proteins that recognize the FC fragment of antibodies, mainly on immune cells. However, recent studies have shown that different subsets of Fc receptors may play a role in tumour cells (Nelson et al., 2001). In particular, it was shown that T47D cells express the FcγRI (CD64). These FC-receptor expressing breast cancer cells can activate the tyrosine kinase signal transduction pathway. Indeed, T47D cells treated with selective tyrosine kinase inhibitors do not proliferate in a FC receptor- tyrosine kinase signalling dependent manner (Nelson et al., 2001).

As mentioned before (Fig. S6C), another pathway identified as activated in response to progestin is the ERBB-EGF network (Fig. S7D and H). ERBB2 (HER2) is overexpressed in 15-20% of breast cancer in response to EGF activation, and plays a major role in EMT (Elizalde et al., 2016). PR interacts with ERBBs and induces the translocation of ERBB2-PR-STAT3 complex to the nucleus. ERBB2 acts as a co-activator of STAT3 and drives the activation of progestin regulated genes, especially genes such as Cyclin D1 that do not contain a HREs (Beguelin et al., 2010; Hsu and Hung, 2016). Blocking PR signalling in PR-ERBB2 positive breast cancer patients has been suggested as a treatment (Proietti et al., 2009). The ERBB pathway may represent a new mechanism for further study to understand the activation of these “non-classical” PR dependent genes in response to progestin. In addition to the role of ERBB2, the role of ER activation in response to progesterone in breast cancer cells is also critical, as shown in Fig. 4C we observe the coordinated activation of the ESR1-Src-PIK3 complex peaking at 15 minutes following hormone exposure. The phosphorylation site of ESR1

which increases is S104. ER S104 phosphorylation is essential for ER activity (Thomas et al 2008) and it has been suggested that hyperphosphorylation of ER at these sites may contribute to resistance to tamoxifen in hormone receptor positive breast cancer (Leeuw et al 2011, Jeffreys et al 2020, Skliris et al 2010). ER S104 phosphorylation by ERK has been shown previously in response to estrogen and EGF but not progesterone exposure. In addition, ER S104 has been implicated in mTOR signaling (Alayev et al 2016). Given the phosphorylation of ER, the dynamic activation of the ER membrane complex and the role of mTOR in AMPK and insulin signalling described earlier (Fig. 3J and 4C) this phosphorylation site may present a key step in the cellular response to progesterone in breast cancer.

A pathway exhibiting strong activation by progestins is the Insulin signalling (Fig. S6C, Fig. S7F). Insulin-like growth factors (IGFs) and progestins both play a major role in normal mammary gland development and R5020 has been shown to induce the expression of insulin receptor substrate-2 in MCF7 cells (Cui et al., 2003a; Cui et al., 2003b). Moreover, IGF signalling via IRS2 is known to be essential for breast cancer cell migration. It has also been shown that R5020 pretreatment followed by IGF stimulation increases binding of IRS to PI3K-p85 regulatory complex, which in turn activates ERK and AKT signalling (Ibrahim et al., 2008). Interestingly, not only do we observe the activation of the insulin pathway in network analysis (Fig. S7F, but the coordinated phosphorylation of all members of the IRS-PIK3 complex was also identified (Fig. 4A), indicating that indeed progesterone stimulation of breast cancer cells activates the not only the insulin pathway but the coordinated regulation of complexes within it.

Discussion

The data presented in this paper provides a source of knowledge for the scientific community with regards to progesterone induced gene expression, and the signalling pathways involved. We have shown the rapid induction of phosphorylation using two distinct technologies (Fig. 1 and 2). Pathway analysis showed a strong enrichment in pathways associated with cancer, known and novel Pg-dependent signalling events (Fig. 3A). But also identified signalling pathways not previously known to mediate progesterone action in breast cancer cells, such as MNK1/EIF4E pathway and the connection between CDK2, Cdc25 and the MAPK pathway.

Cellular component analysis confirmed our expectations and the statistically significant activation of the cell membrane within 1 minute of hormone exposure (Fig. 3B), but also revealed a consistent (over all members) phosphorylation peak within proteins associated within the mitochondria at 15 minutes after hormone exposure (Fig. 3B and S4E). Mitochondrial activation in response to progesterone in breast cancer cells has not been extensively studied yet. Indeed, ATP synthesis 45-60 minutes after hormone stimulation is independent of mitochondrial involvement (Wright et al., 2016). However, there are some interesting findings in the literature. Following the observation that the PR negative cell line MCF10A exhibits a progestin-induced cell proliferation (Kramer et al., 2006). Behera and colleagues showed that MCF10A respond to R5020 with an increase in mitochondrial activation (Behera et al., 2009). Given the absence of the nuclear PR in these cells they hypothesized that the activation of progestin-induced cell growth was due to non-genomic metabolic effects, mediated by a yet undiscovered receptor. We propose that the observed mitochondrial activation in T47D in response to progestin (Fig. 3B and S4E) suggests the existence of a third and interconnected hormonal signal transduction pathway via the mitochondria (Demonacos et al., 1996; Hatzoglou and Sekeris, 1997).

634 Dynamic phosphorylation analysis over time reveals distinct groups or clusters
635 of phosphorylation events which follow a similar time response; such as early risers,
636 sustained or late (Fig. 3C). Similarity analysis of these dynamic phosphorylation sites
637 reveals some interesting crosstalk between protein complexes not previously identified
638 as players in progesterone signalling in breast cancer cells (Supplementary Table S6),
639 and complexes where a mobilization of phosphorylation (showing similar dynamics)
640 was observed within the whole macromolecular complex; such as PIK3, NFkB (Fig.
641 4B and C).

642 Overlap of phosphorylation sites with existing PARylation, revealed 52 proteins
643 for which both phosphorylation and PARylation was found. The data also clearly shows
644 an enrichment in protein complexes that play a role in the structural organisation of the
645 nucleus (Fig. 4D and E), specifically the Emerin complex and Lamin (Fig. 4G). The
646 key location of these complexes at the nuclear membrane, suggests that perhaps these
647 two PTMs may affect and play a role in the dynamic structure of the nucleus. This could
648 be explored in the future by global chromatin proximity Hi-C experiments. The
649 complexes identified in this study and the dual post translational modification of
650 proteins with known important roles within the cell may provide exciting opportunities
651 for future studies which aim to understand the crosstalk between Serine PARylation
652 and phosphorylation in the context of nuclear architecture, signalling and breast cancer
653 progression (Supplementary Table S7).

654 In addition to pathway analysis at the single network level (Fig. S7), wherein
655 we identified pathways such as insulin, Fc-receptor and ERBB signalling, it is also
656 clearly important to consider the connection between pathways and networks as a
657 whole. One such example, is the connections between the phosphorylation events
658 within the cytoskeleton, membrane raft and proteins associated with cell adhesion. We

observe phosphorylation events in multiple proteins within both cell adhesion and the membrane raft, forming tight strongly connected PPI networks (Fig. 5A). A network merge of these two pathways reveals 4 key proteins which are present in both (JAK2, SRC1, LYN and KDR), indicating a strongly connected network (Fig. 5B), which in addition to common members exhibits a large first neighbour selection between the two initial pathways (selection of only direct PPI) (Fig. 5B right panel) with a similar phosphokinetic pattern (Fig. 5C). Incorporation of the significantly enriched phosphorylated proteins within the cytoskeleton (Fig. 3B, Fig. S6D, Supplementary table S3) into the merged network (Fig. 5B) results in a larger global connected network (Fig. 5D) which supports the activation within the membrane proteins after 1-minute following hormone exposure that triggers the subsequent cascades of phosphorylation in the cytoskeleton (Fig. 5E). These findings clearly show the importance of studying the pathways not in isolation, but rather in connection with each other.

Other examples of connectivity are observed between the ERK subgroup and the MAPK cascades and the FC Receptor and TRK signalling. ERK and MAPK form a strong network (Fig. 6A and B). As discussed, earlier Fc-receptor signalling shows a strong activation (Fig. S7B). The tropomyosin receptor tyrosine kinases (TRKs) are primarily known for their roles in neuronal differentiation and survival. However, increasing evidence shows that TRK receptors can be found in a host of mammalian cell types to drive several cellular responses (Huang and Reichardt, 2003; Reichardt, 2006) Aberrations in TRK signalling, which can occur through events such as protein overexpression, alternative splicing, or gene amplification, can lead to disease such as cancer (Jin, 2020; Meng et al., 2019; Regua et al., 2019). The receptor tyrosine kinase NTRK2, activates GRB2-Ras-MAPK cascade in neurons and increases secretion by epithelial cells in culture in response to estrogen or progestin treatment and NTRK2

was identified as differentially expressed between stromal and epithelial breast cells which may have implications in invasion and metastasis (Wang et al., 2020) Merging of Fc-receptor and TRK signalling pathways (Fig. 6C) shows a strong protein overlap and a dense connected network with FOXO1 at the center (Fig. 6D). and FOXO1 is phosphorylated after 1 to 5 minutes of progestin exposure (Fig. 6E). Phosphorylation of FOXO1 by PKB/Akt has been shown to be important for the binding to 14-3-3 proteins on chromatin (Dobson et al., 2011; Pennington et al., 2018; Tzivion et al., 2011; Tzivion and Hay, 2011). The role of these two pathways in progesterone induced gene regulation has not been shown previously. FOXO factors have a key role to play in tumour resistance to therapy and patient outcome (Bullock, 2016). Interestingly, from a clinical perspective, stratifying patients based on either the expression levels of NTRK2 (TRKB) or FOXO1 is predictive of a good prognosis (overall survival) in breast cancer, similar to prognosis based on PR expression (Fig. 6F and G). The examples described here in addition to other examples contained within the data for future discovery show the importance of network connectivity in trying to understand not only individual proteins or pathways but the significant overlap between the pathways within the signalling network activated by progesterone in breast cancer. Further analysis of the detected connections and identification of the key regulators may provide a source of targets for drug discovery aiming at the treatment of hormone receptor positive breast cancer patients.

Conclusions

The data presented here, reveals a high level of complexity in progesterone signalling in breast cancer cells, shedding new light on known proteins and signalling pathways. Functional analysis reveals the activation of known pathways such as MAPK cascade

but also the activation of signalling cascades not previously associated with progesterone signalling such as TRK, TNF α and ERBB. Our analysis indicates that there is a full cellular coordinated response, with proteins activated in different cellular compartments at different times following hormone exposure, in addition to the activation of whole protein complexes previously not associated with progesterone signalling. We believe that this signalling network and the phosphosites identified represent a rich resource for the breast cancer research community, opening up new lines of research and ideas for possible drug discovery projects for the benefit of breast cancer patients.

List of abbreviations

AKT: AKT serine/threonine kinase 1
ARTD1: ADP-ribosyltransferase diphtheria toxin-like 1
ATP: Adenosine tri-phosphate
BAF: BRG1-associated factor 53A
BCA: Bicinchoninic acid
CAMKK1: Calcium/calmodulin-dependent protein kinase kinase 1
CDK1/2: Cyclin dependent kinase
EMT: Epithelial to mesenchyme transition
ER: Estrogen receptor
ERBB: Receptor tyrosine-protein kinase erbB-2
ERK1: Extracellular signal-regulated kinase 1
KH: K homology
MNK1: MAP kinase signal-integrated kinase 1

734 MSK: Mitogen and stress activated protein kinase 1
735 NUDT5: Nucleoside diphosphate-linked moiety X motif 5
736 NURF: Nucleosome-remodeling factor subunit
737 PAR: Poly-ADP-ribose
738 PARG: Poly-ADP-ribose glycohydrolase
739 PARP1: Poly-ADP-ribose polymerase
740 PCA: Principle component analysis
741 PGR : Progesterone Receptor
742 PKN : Prior knowledge network
743 PML: Prommyelocytic leukaemia
744 PPI: Protein protein interaction
745 PRE: Progesterone responsive element

746

747

748 **Declarations**

749

750 **Ethics and approval and consent to participate**

751 Not applicable

752

753 **Consent for publication**

754 Not applicable

755

756 **Availability of data and materials**

757 The datasets used and analysed during the current study are included in this published
758 article within supplementary tables (Supp Table 1).

759

760 **Competing Interests**

761 The authors declare that they have no competing interests.

762

763 **Funding**

764 This research was supported by European Research Council (Project “4D Genome”
765 609989), the Ministerio de Economía y Competitividad (Project G62426937) and
766 the Generalitat de Catalunya (Project AGAUR SGR 575). European Research
767 Council -Proof Of Concept (Project “Impacct” 825176).

768

769 **Authors contributions**

770 Experimental design; R.H.G.W and M.B. Bioinformatic Analysis; J. Q. O., J.C.C and
771 R.W. Manuscript writing and editing; R.H.G.W and M.B. Experiments; R.W. “All
772 authors read and approved the final manuscript.”

773

774 **Acknowledgements**

775 We acknowledge the support of all members of the Chromatin, Gene Regulation
776 laboratory and members of the Gene Regulation Cancer and Stem Cells department at
777 Centre for Genomic Regulation (CRG, Barcelona Spain).

778

779 **References**

780

781 Ballare, C., Uhrig, M., Bechtold, T., Sancho, E., Di Domenico, M., Migliaccio, A.,
782 Auricchio, F., and Beato, M. (2003). Two domains of the progesterone receptor interact

783 with the estrogen receptor and are required for progesterone activation of the c-Src/Erk
784 pathway in mammalian cells. *Mol Cell Biol* 23, 1994-2008.

785 Beato, M., Herrlich, P., and Schutz, G. (1995). Steroid hormone receptors: many actors
786 in search of a plot. *Cell* 83, 851-857.

787 Beguelin, W., Diaz Flaquer, M.C., Proietti, C.J., Cayrol, F., Rivas, M.A., Tkach, M.,
788 Rosemblit, C., Tocci, J.M., Charreau, E.H., Schillaci, R., *et al.* (2010). Progesterone
789 receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a
790 novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. *Mol Cell Biol*
791 30, 5456-5472.

792 Behera, M.A., Dai, Q., Garde, R., Saner, C., Jungheim, E., and Price, T.M. (2009).
793 Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis
794 in MCF-10A benign breast epithelial cells. *Am J Physiol Endocrinol Metab* 297,
795 E1089-1096.

796 Bonfiglio, J.J., Colby, T., and Matic, I. (2017a). Mass spectrometry for serine ADP-
797 ribosylation? Think o-glycosylation! *Nucleic Acids Res* 45, 6259-6264.

798 Bonfiglio, J.J., Fontana, P., Zhang, Q., Colby, T., Gibbs-Seymour, I., Atanassov, I.,
799 Bartlett, E., Zaja, R., Ahel, I., and Matic, I. (2017b). Serine ADP-Ribosylation Depends
800 on HPF1. *Mol Cell* 65, 932-940 e936.

801 Boonyaratanakornkit, V., Bi, Y., Rudd, M., and Edwards, D.P. (2008). The role and
802 mechanism of progesterone receptor activation of extra-nuclear signaling pathways in
803 regulating gene transcription and cell cycle progression. *Steroids* 73, 922-928.

804 Boonyaratanakornkit, V., McGowan, E., Sherman, L., Mancini, M.A., Cheskis, B.J.,
805 and Edwards, D.P. (2007). The role of extranuclear signaling actions of progesterone
806 receptor in mediating progesterone regulation of gene expression and the cell cycle.
807 *Mol Endocrinol* 21, 359-375.

808 Boonyaratanakornkit, V., Scott, M.P., Ribon, V., Sherman, L., Anderson, S.M., Maller,
809 J.L., Miller, W.T., and Edwards, D.P. (2001). Progesterone receptor contains a proline-
810 rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine
811 kinases. *Mol Cell* 8, 269-280.

812 Bullock, M. (2016). FOXO factors and breast cancer: outfoxing endocrine resistance.
813 *Endocr Relat Cancer* 23, R113-130.

814 Cabodi, S., Moro, L., Baj, G., Smeriglio, M., Di Stefano, P., Gippone, S., Surico, N.,
815 Silengo, L., Turco, E., Tarone, G., *et al.* (2004). p130Cas interacts with estrogen
816 receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. *J*
817 *Cell Sci* 117, 1603-1611.

818 Cabodi, S., Tinnirello, A., Di Stefano, P., Bisaro, B., Ambrosino, E., Castellano, I.,
819 Sapino, A., Arisio, R., Cavallo, F., Forni, G., *et al.* (2006). p130Cas as a new regulator
820 of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent
821 breast tumorigenesis. *Cancer Res* 66, 4672-4680.

822 Cheadle, C., Cho-Chung, Y.S., Becker, K.G., and Vawter, M.P. (2003). Application of
823 z-score transformation to Affymetrix data. *Appl Bioinformatics* 2, 209-217.

824 Ciruelos Gil, E.M. (2014). Targeting the PI3K/AKT/mTOR pathway in estrogen
825 receptor-positive breast cancer. *Cancer Treat Rev* 40, 862-871.

826 Cui, X., Lazard, Z., Zhang, P., Hopp, T.A., and Lee, A.V. (2003a). Progesterone
827 crosstalks with insulin-like growth factor signaling in breast cancer cells via induction
828 of insulin receptor substrate-2. *Oncogene* 22, 6937-6941.

829 Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G.B., and Lee, A.V.
830 (2003b). Insulin-like growth factor-I inhibits progesterone receptor expression in breast
831 cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin
832 pathway: progesterone receptor as a potential indicator of growth factor activity in
833 breast cancer. *Mol Endocrinol* 17, 575-588.

834 Dai, Q., Likes, C.E., 3rd, Luz, A.L., Mao, L., Yeh, J.S., Wei, Z., Kuchibhatla, M.,
835 Ilkayeva, O.R., Koves, T.R., and Price, T.M. (2019). A Mitochondrial Progesterone
836 Receptor Increases Cardiac Beta-Oxidation and Remodeling. *J Endocr Soc* 3, 446-467.

837 Demonacos, C.V., Karayanni, N., Hatzoglou, E., Tsiriyiotis, C., Spandidos, D.A., and
838 Sekeris, C.E. (1996). Mitochondrial genes as sites of primary action of steroid
839 hormones. *Steroids* 61, 226-232.

840 Dobson, M., Ramakrishnan, G., Ma, S., Kaplun, L., Balan, V., Fridman, R., and
841 Tzivion, G. (2011). Bimodal regulation of FoxO3 by AKT and 14-3-3. *Biochim*
842 *Biophys Acta* 1813, 1453-1464.

843 Dolniak, B., Katsoulidis, E., Carayol, N., Altman, J.K., Redig, A.J., Tallman, M.S.,
844 Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., and Plataniias, L.C. (2008).
845 Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. *J Biol*
846 *Chem* 283, 12034-12042.

847 Elizalde, P.V., Cordo Russo, R.I., Chervo, M.F., and Schillaci, R. (2016). ErbB-2
848 nuclear function in breast cancer growth, metastasis and resistance to therapy. *Endocr*
849 *Relat Cancer* 23, T243-T257.

850 Eto, I. (2010). Upstream molecular signaling pathways of p27(Kip1) expression: effects
851 of 4-hydroxytamoxifen, dexamethasone, and retinoic acids. *Cancer Cell Int* 10, 3.

852 Faivre, E., Skildum, A., Pierson-Mullany, L., and Lange, C.A. (2005). Integration of
853 progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell
854 models: role of mitogen-activated protein kinases and cell cycle regulators. *Steroids* 70,
855 418-426.

856 Fu, X.D., Goglia, L., Sanchez, A.M., Flamini, M., Giretti, M.S., Tosi, V., Genazzani,
857 A.R., and Simoncini, T. (2010). Progesterone receptor enhances breast cancer cell
858 motility and invasion via extranuclear activation of focal adhesion kinase. *Endocr Relat*
859 *Cancer* 17, 431-443.

860 Garg, D., Ng, S.S.M., Baig, K.M., Driggers, P., and Segars, J. (2017). Progesterone-
861 Mediated Non-Classical Signaling. *Trends Endocrinol Metab* 28, 656-668.

862 Gonzalez-Suarez, E., Jacob, A.P., Jones, J., Miller, R., Roudier-Meyer, M.P., Erwert,
863 R., Pinkas, J., Branstetter, D., and Dougall, W.C. (2010). RANK ligand mediates
864 progestin-induced mammary epithelial proliferation and carcinogenesis. *Nature* 468,
865 103-107.

866 Grimmmler, M., Wang, Y., Mund, T., Cilensek, Z., Keidel, E.M., Waddell, M.B., Jakel,
867 H., Kullmann, M., Kriwacki, R.W., and Hengst, L. (2007). Cdk-inhibitory activity and

868 stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. *Cell* 128,
869 269-280.

870 Guo, Q., Li, V.Z., Nichol, J.N., Huang, F., Yang, W., Preston, S.E.J., Talat, Z., Lefrere,
871 H., Yu, H., Zhang, G., *et al.* (2019). MNK1/NODAL Signaling Promotes Invasive
872 Progression of Breast Ductal Carcinoma In Situ. *Cancer Res* 79, 1646-1657.

873 Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., and Szallasi,
874 Z. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes
875 on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res*
876 *Treat* 123, 725-731.

877 Hadad, S.M., Fleming, S., and Thompson, A.M. (2008). Targeting AMPK: a new
878 therapeutic opportunity in breast cancer. *Crit Rev Oncol Hematol* 67, 1-7.

879 Hagan, C.R., Knutson, T.P., and Lange, C.A. (2013). A Common Docking Domain in
880 Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative
881 transcriptional programs in breast cancer cells. *Nucleic Acids Res* 41, 8926-8942.

882 Hassa, P.O., Haenni, S.S., Elser, M., and Hottiger, M.O. (2006). Nuclear ADP-
883 ribosylation reactions in mammalian cells: where are we today and where are we going?
884 *Microbiol Mol Biol Rev* 70, 789-829.

885 Hatzoglou, E., and Sekeris, C.E. (1997). The detection of nucleotide sequences with
886 strong similarity to hormone responsive elements in the genome of eubacteria and
887 archaeobacteria and their possible relation to similar sequences present in the
888 mitochondrial genome. *J Theor Biol* 184, 339-344.

889 Haverinen, M., Passinen, S., Syvala, H., Pasanen, S., Manninen, T., Tuohimaa, P., and
890 Ylikomi, T. (2001). Heat shock protein 90 and the nuclear transport of progesterone
891 receptor. *Cell Stress Chaperones* 6, 256-262.

892 Hiratani, K., Haruta, T., Tani, A., Kawahara, J., Usui, I., and Kobayashi, M. (2005).
893 Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of
894 IRS-1. *Biochem Biophys Res Commun* 335, 836-842.

895 Hoch, N.C., and Polo, L.M. (2019). ADP-ribosylation: from molecular mechanisms to
896 human disease. *Genet Mol Biol* 43, e20190075.

897 Holaska, J.M., and Wilson, K.L. (2007). An emerin "proteome": purification of distinct
898 emerin-containing complexes from HeLa cells suggests molecular basis for diverse
899 roles including gene regulation, mRNA splicing, signaling, mechanosensing, and
900 nuclear architecture. *Biochemistry* 46, 8897-8908.

901 Hsu, J.L., and Hung, M.C. (2016). The role of HER2, EGFR, and other receptor
902 tyrosine kinases in breast cancer. *Cancer Metastasis Rev* 35, 575-588.

903 Huang, E.J., and Reichardt, L.F. (2003). Trk receptors: roles in neuronal signal
904 transduction. *Annu Rev Biochem* 72, 609-642.

905 Hurley, R.L., Anderson, K.A., Franzone, J.M., Kemp, B.E., Means, A.R., and Witters,
906 L.A. (2005). The Ca^{2+} /calmodulin-dependent protein kinase kinases are AMP-
907 activated protein kinase kinases. *J Biol Chem* 280, 29060-29066.

908 Ibrahim, Y.H., Byron, S.A., Cui, X., Lee, A.V., and Yee, D. (2008). Progesterone
909 receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast
910 cancer cells via insulin receptor substrate-2. *Mol Cancer Res* 6, 1491-1498.

911 Jin, W. (2020). Roles of TrkC Signaling in the Regulation of Tumorigenicity and
 912 Metastasis of Cancer. *Cancers (Basel)* 12.

913 Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige,
 914 S., Gotoh, Y., Nishida, E., Kawashima, H., *et al.* (1995). Activation of the estrogen
 915 receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270,
 916 1491-1494.

917 Knotts, T.A., Orkiszewski, R.S., Cook, R.G., Edwards, D.P., and Weigel, N.L. (2001).
 918 Identification of a phosphorylation site in the hinge region of the human progesterone
 919 receptor and additional amino-terminal phosphorylation sites. *J Biol Chem* 276, 8475-
 920 8483.

921 Knutson, T.P., Truong, T.H., Ma, S., Brady, N.J., Sullivan, M.E., Raj, G., Schwertfeger,
 922 K.L., and Lange, C.A. (2017). Posttranslationally modified progesterone receptors
 923 direct ligand-specific expression of breast cancer stem cell-associated gene programs.
 924 *J Hematol Oncol* 10, 89.

925 Kramer, E.A., Seeger, H., Kramer, B., Wallwiener, D., and Mueck, A.O. (2006).
 926 Characterization of the stimulatory effect of medroxyprogesterone acetate and
 927 chlormadinone acetate on growth factor treated normal human breast epithelial cells. *J*
 928 *Steroid Biochem Mol Biol* 98, 174-178.

929 Lange, C.A. (2008). Integration of progesterone receptor action with rapid signaling
 930 events in breast cancer models. *J Steroid Biochem Mol Biol* 108, 203-212.

931 Lange, C.A., Shen, T., and Horwitz, K.B. (2000). Phosphorylation of human
 932 progesterone receptors at serine-294 by mitogen-activated protein kinase signals their
 933 degradation by the 26S proteasome. *Proc Natl Acad Sci U S A* 97, 1032-1037.

934 Le Dily, F., Vidal, E., Cuartero, Y., Quilez, J., Nacht, A.S., Vicent, G.P., Carbonell-
 935 Caballero, J., Sharma, P., Villanueva-Canas, J.L., Ferrari, R., *et al.* (2019). Hormone-
 936 control regions mediate steroid receptor-dependent genome organization. *Genome Res*
 937 29, 29-39.

938 Lee, H., and Kim, J.J. (2014). Influence of AKT on progesterone action in endometrial
 939 diseases. *Biol Reprod* 91, 63.

940 Leidecker, O., Bonfiglio, J.J., Colby, T., Zhang, Q., Atanassov, I., Zaja, R., Palazzo,
 941 L., Stockum, A., Ahel, I., and Matic, I. (2016). Serine is a new target residue for
 942 endogenous ADP-ribosylation on histones. *Nat Chem Biol* 12, 998-1000.

943 Leung, A.K. (2014). Poly(ADP-ribose): an organizer of cellular architecture. *J Cell Biol*
 944 205, 613-619.

945 Li, X., Wong, J., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. (2003). Progesterone and
 946 glucocorticoid receptors recruit distinct coactivator complexes and promote distinct
 947 patterns of local chromatin modification. *Mol Cell Biol* 23, 3763-3773.

948 Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdottir, H., Tamayo, P., and
 949 Mesirov, J.P. (2011). Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27,
 950 1739-1740.

951 Liu, Q., Florea, B.I., and Filippov, D.V. (2017). ADP-Ribosylation Goes Normal:
 952 Serine as the Major Site of the Modification. *Cell Chem Biol* 24, 431-432.

953 Malbeteau, L., Poulard, C., Languilaire, C., Mikaelian, I., Flamant, F., Le Romancer,
 954 M., and Corbo, L. (2020). PRMT1 Is Critical for the Transcriptional Activity and the
 955 Stability of the Progesterone Receptor. *iScience* 23, 101236.

956 Mamay, C.L., Mingo-Sion, A.M., Wolf, D.M., Molina, M.D., and Van Den Berg, C.L.
 957 (2003). An inhibitory function for JNK in the regulation of IGF-I signaling in breast
 958 cancer. *Oncogene* 22, 602-614.

959 Martello, R., Leutert, M., Jungmichel, S., Bilan, V., Larsen, S.C., Young, C., Hottiger,
 960 M.O., and Nielsen, M.L. (2016). Proteome-wide identification of the endogenous ADP-
 961 ribosylome of mammalian cells and tissue. *Nat Commun* 7, 12917.

962 McInnes, K.J., Brown, K.A., Hunger, N.I., and Simpson, E.R. (2012). Regulation of
 963 LKB1 expression by sex hormones in adipocytes. *Int J Obes (Lond)* 36, 982-985.

964 McInnes, K.J., Corbould, A., Simpson, E.R., and Jones, M.E. (2006). Regulation of
 965 adenosine 5',monophosphate-activated protein kinase and lipogenesis by androgens
 966 contributes to visceral obesity in an estrogen-deficient state. *Endocrinology* 147, 5907-
 967 5913.

968 McKay, M.M., Ritt, D.A., and Morrison, D.K. (2009). Signaling dynamics of the KSR1
 969 scaffold complex. *Proc Natl Acad Sci U S A* 106, 11022-11027.

970 Meng, L., Liu, B., Ji, R., Jiang, X., Yan, X., and Xin, Y. (2019). Targeting the
 971 BDNF/TrkB pathway for the treatment of tumors. *Oncol Lett* 17, 2031-2039.

972 Messner, S., Altmeyer, M., Zhao, H., Pozivil, A., Roschitzki, B., Gehrig, P.,
 973 Rutishauser, D., Huang, D., Caflisch, A., and Hottiger, M.O. (2010). PARP1 ADP-
 974 ribosylates lysine residues of the core histone tails. *Nucleic Acids Res* 38, 6350-6362.

975 Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi,
976 M., Gong, W., Beato, M., and Auricchio, F. (1998). Activation of the Src/p21ras/Erk
977 pathway by progesterone receptor via cross-talk with estrogen receptor. *EMBO J* 17,
978 2008-2018.

979 Montero, J.C., Esparis-Ogando, A., Re-Louhau, M.F., Seoane, S., Abad, M., Calero,
980 R., Ocana, A., and Pandiella, A. (2014). Active kinase profiling, genetic and
981 pharmacological data define mTOR as an important common target in triple-negative
982 breast cancer. *Oncogene* 33, 148-156.

983 Nacht, A.S., Pohl, A., Zaurin, R., Soronellas, D., Quilez, J., Sharma, P., Wright, R.H.,
984 Beato, M., and Vicent, G.P. (2016). Hormone-induced repression of genes requires
985 BRG1-mediated H1.2 deposition at target promoters. *EMBO J* 35, 1822-1843.

986 Nelson, M.B., Nyhus, J.K., Oravec-Wilson, K.I., and Barbera-Guillem, E. (2001).
987 Tumor cells express FcγRI which contributes to tumor cell growth and a
988 metastatic phenotype. *Neoplasia* 3, 115-124.

989 Ortega, M.A., Fraile-Martinez, O., Asunsolo, A., Bujan, J., Garcia-Honduvilla, N., and
990 Coca, S. (2020). Signal Transduction Pathways in Breast Cancer: The Important Role
991 of PI3K/Akt/mTOR. *J Oncol* 2020, 9258396.

992 Park, J., Wood, M.A., and Cole, M.D. (2002). BAF53 forms distinct nuclear complexes
993 and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic
994 transformation. *Mol Cell Biol* 22, 1307-1316.

995 Paul, A., Edwards, J., Pepper, C., and Mackay, S. (2018). Inhibitory-kappaB Kinase
 996 (IKK) alpha and Nuclear Factor-kappaB (NFkappaB)-Inducing Kinase (NIK) as Anti-
 997 Cancer Drug Targets. *Cells* 7.

998 Pedram, A., Razandi, M., Sainson, R.C., Kim, J.K., Hughes, C.C., and Levin, E.R.
 999 (2007). A conserved mechanism for steroid receptor translocation to the plasma
 1000 membrane. *J Biol Chem* 282, 22278-22288.

1001 Pennington, K.L., Chan, T.Y., Torres, M.P., and Andersen, J.L. (2018). The dynamic
 1002 and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and
 1003 context-dependent protein-protein interactions. *Oncogene* 37, 5587-5604.

1004 Pickup, K.E., Pardow, F., Carbonell-Caballero, J., Lioutas, A., Villanueva-Canas, J.L.,
 1005 Wright, R.H.G., and Beato, M. (2019). Expression of Oncogenic Drivers in 3D Cell
 1006 Culture Depends on Nuclear ATP Synthesis by NUDT5. *Cancers (Basel)* 11.

1007 Pina, B., Bruggemeier, U., and Beato, M. (1990). Nucleosome positioning modulates
 1008 accessibility of regulatory proteins to the mouse mammary tumor virus promoter. *Cell*
 1009 60, 719-731.

1010 Price, T.M., and Dai, Q. (2015). The Role of a Mitochondrial Progesterone Receptor
 1011 (PR-M) in Progesterone Action. *Semin Reprod Med* 33, 185-194.

1012 Proietti, C.J., Rosembliet, C., Beguelin, W., Rivas, M.A., Diaz Flaquer, M.C., Charreau,
 1013 E.H., Schillaci, R., and Elizalde, P.V. (2009). Activation of Stat3 by heregulin/ErbB-2
 1014 through the co-option of progesterone receptor signaling drives breast cancer growth.
 1015 *Mol Cell Biol* 29, 1249-1265.

1016 Qiu, M., Olsen, A., Faivre, E., Horwitz, K.B., and Lange, C.A. (2003). Mitogen-
1017 activated protein kinase regulates nuclear association of human progesterone receptors.
1018 *Mol Endocrinol* 17, 628-642.

1019 Ranade, D., Pradhan, R., Jayakrishnan, M., Hegde, S., and Sengupta, K. (2019). Lamin
1020 A/C and Emerin depletion impacts chromatin organization and dynamics in the
1021 interphase nucleus. *BMC Mol Cell Biol* 20, 11.

1022 Regua, A.T., Doheny, D., Arrigo, A., and Lo, H.W. (2019). Trk receptor tyrosine
1023 kinases in metastasis and cancer therapy. *Discov Med* 28, 195-203.

1024 Reichardt, L.F. (2006). Neurotrophin-regulated signalling pathways. *Philos Trans R*
1025 *Soc Lond B Biol Sci* 361, 1545-1564.

1026 Rider, V., Isuzugawa, K., Twarog, M., Jones, S., Cameron, B., Imakawa, K., and Fang,
1027 J. (2006). Progesterone initiates Wnt-beta-catenin signaling but estradiol is required for
1028 nuclear activation and synchronous proliferation of rat uterine stromal cells. *J*
1029 *Endocrinol* 191, 537-548.

1030 Sanchez-Margalet, V., and Najib, S. (2001). Sam68 is a docking protein linking GAP
1031 and PI3K in insulin receptor signaling. *Mol Cell Endocrinol* 183, 113-121.

1032 Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J.A., Lee, H.J., Hanada,
1033 R., Joshi, P.A., Aliprantis, A., Glimcher, L., *et al.* (2010). Osteoclast differentiation
1034 factor RANKL controls development of progestin-driven mammary cancer. *Nature*
1035 468, 98-102.

1036 Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N.,
1037 Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for
1038 integrated models of biomolecular interaction networks. *Genome Res* 13, 2498-2504.

1039 Shostak, K., and Chariot, A. (2011). NF-kappaB, stem cells and breast cancer: the links
1040 get stronger. *Breast Cancer Res* 13, 214.

1041 Skildum, A., Faivre, E., and Lange, C.A. (2005). Progesterone receptors induce cell
1042 cycle progression via activation of mitogen-activated protein kinases. *Mol Endocrinol*
1043 19, 327-339.

1044 Smith, D.F. (1993). Dynamics of heat shock protein 90-progesterone receptor binding
1045 and the disactivation loop model for steroid receptor complexes. *Mol Endocrinol* 7,
1046 1418-1429.

1047 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette,
1048 M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., *et al.* (2005). Gene set
1049 enrichment analysis: a knowledge-based approach for interpreting genome-wide
1050 expression profiles. *Proc Natl Acad Sci U S A* 102, 15545-15550.

1051 Takahashi, A., Kato, K., Kuboyama, A., Inoue, T., Tanaka, Y., Kuhara, A., Kinoshita,
1052 K., Takeda, S., and Wake, N. (2009). Induction of senescence by progesterone receptor-
1053 B activation in response to cAMP in ovarian cancer cells. *Gynecol Oncol* 113, 270-276.

1054 Thomas, C., and Tulin, A.V. (2013). Poly-ADP-ribose polymerase: machinery for
1055 nuclear processes. *Mol Aspects Med* 34, 1124-1137.

1056 Trevino, L.S., Bolt, M.J., Grimm, S.L., Edwards, D.P., Mancini, M.A., and Weigel,
1057 N.L. (2016). Differential Regulation of Progesterone Receptor-Mediated Transcription
1058 by CDK2 and DNA-PK. *Mol Endocrinol* 30, 158-172.

1059 Tzatsos, A. (2009). Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of
1060 insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-
1061 636/639 by mTOR. *J Biol Chem* 284, 22525-22534.

1062 Tzivion, G., Dobson, M., and Ramakrishnan, G. (2011). FoxO transcription factors;
1063 Regulation by AKT and 14-3-3 proteins. *Biochim Biophys Acta* 1813, 1938-1945.

1064 Tzivion, G., and Hay, N. (2011). PI3K-AKT-FoxO axis in cancer and aging. *Biochim*
1065 *Biophys Acta* 1813, 1925.

1066 Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
1067 Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., *et al.* (2015). Proteomics. Tissue-
1068 based map of the human proteome. *Science* 347, 1260419.

1069 Valverde, A.M., Arribas, M., Mur, C., Navarro, P., Pons, S., Cassard-Doulcier, A.M.,
1070 Kahn, C.R., and Benito, M. (2003). Insulin-induced up-regulated uncoupling protein-1
1071 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol
1072 3-kinase/Akt signaling pathway in fetal brown adipocytes. *J Biol Chem* 278, 10221-
1073 10231.

1074 Vicent, G.P., Ballare, C., Nacht, A.S., Clausell, J., Subtil-Rodriguez, A., Quiles, I.,
1075 Jordan, A., and Beato, M. (2006). Induction of progesterone target genes requires
1076 activation of Erk and Msk kinases and phosphorylation of histone H3. *Mol Cell* 24,
1077 367-381.

1078 Vicent, G.P., Nacht, A.S., Font-Mateu, J., Castellano, G., Gaveglia, L., Ballare, C., and
1079 Beato, M. (2011). Four enzymes cooperate to displace histone H1 during the first
1080 minute of hormonal gene activation. *Genes Dev* 25, 845-862.

1081 Vicent, G.P., Wright, R.H., and Beato, M. (2016). Linker histones in hormonal gene
1082 regulation. *Biochim Biophys Acta* 1859, 520-525.

1083 Vicent, G.P., Zaurin, R., Ballare, C., Nacht, A.S., and Beato, M. (2009a). Erk signaling
1084 and chromatin remodeling in MMTV promoter activation by progestins. *Nucl Recept*
1085 *Signal* 7, e008.

1086 Vicent, G.P., Zaurin, R., Nacht, A.S., Font-Mateu, J., Le Dily, F., and Beato, M. (2010).
1087 Nuclear factor 1 synergizes with progesterone receptor on the mouse mammary tumor
1088 virus promoter wrapped around a histone H3/H4 tetramer by facilitating access to the
1089 central hormone-responsive elements. *J Biol Chem* 285, 2622-2631.

1090 Vicent, G.P., Zaurin, R., Nacht, A.S., Li, A., Font-Mateu, J., Le Dily, F., Vermeulen,
1091 M., Mann, M., and Beato, M. (2009b). Two chromatin remodeling activities cooperate
1092 during activation of hormone responsive promoters. *PLoS Genet* 5, e1000567.

1093 von Eyss, B., Jaenicke, L.A., Kortlever, R.M., Royla, N., Wiese, K.E., Letschert, S.,
1094 McDuffus, L.A., Sauer, M., Rosenwald, A., Evan, G.I., *et al.* (2015). A MYC-Driven
1095 Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial
1096 Cells and Breast Cancer. *Cancer Cell* 28, 743-757.

1097 Wang, R., Fu, L., Li, J., Zhao, D., Zhao, Y., and Yin, L. (2020). Microarray Analysis
1098 for Differentially Expressed Genes Between Stromal and Epithelial Cells in
1099 Development and Metastasis of Invasive Breast Cancer. *J Comput Biol*.

1100 Wang, Y., Feng, H., Bi, C., Zhu, L., Pollard, J.W., and Chen, B. (2007). GSK-3 β
1101 mediates in the progesterone inhibition of estrogen induced cyclin D2 nuclear
1102 localization and cell proliferation in cyclin D1 $^{-/-}$ mouse uterine epithelium. *FEBS Lett*
1103 *581*, 3069-3075.

1104 Warde-Farley, D., Donaldson, S.L., Comes, O., Zuberi, K., Badrawi, R., Chao, P.,
1105 Franz, M., Grouios, C., Kazi, F., Lopes, C.T., *et al.* (2010). The GeneMANIA
1106 prediction server: biological network integration for gene prioritization and predicting
1107 gene function. *Nucleic Acids Res* *38*, W214-220.

1108 Wheeler, M.J., Johnson, P.W., and Blaydes, J.P. (2010). The role of MNK proteins and
1109 eIF4E phosphorylation in breast cancer cell proliferation and survival. *Cancer Biol Ther*
1110 *10*, 728-735.

1111 Wierer, M., Verde, G., Pisano, P., Molina, H., Font-Mateu, J., Di Croce, L., and Beato,
1112 M. (2013). PLK1 signaling in breast cancer cells cooperates with estrogen receptor-
1113 dependent gene transcription. *Cell Rep* *3*, 2021-2032.

1114 Wright, R.H., Castellano, G., Bonet, J., Le Dily, F., Font-Mateu, J., Ballare, C., Nacht,
1115 A.S., Soronellas, D., Oliva, B., and Beato, M. (2012). CDK2-dependent activation of
1116 PARP-1 is required for hormonal gene regulation in breast cancer cells. *Genes Dev* *26*,
1117 1972-1983.

1118 Wright, R.H., Lioutas, A., Le Dily, F., Soronellas, D., Pohl, A., Bonet, J., Nacht, A.S.,
1119 Samino, S., Font-Mateu, J., Vicent, G.P., *et al.* (2016). ADP-ribose-derived nuclear
1120 ATP synthesis by NUDIX5 is required for chromatin remodeling. *Science* *352*, 1221-
1121 1225.

1122 Wright, R.H.G., Le Dily, F., and Beato, M. (2019). ATP, Mg(2+), Nuclear Phase
 1123 Separation, and Genome Accessibility. *Trends Biochem Sci* 44, 565-574.

1124 Wu, L., Huang, X.J., Yang, C.H., Deng, S.S., Qian, M., Zang, Y., and Li, J. (2011). 5'-
 1125 AMP-activated protein kinase (AMPK) regulates progesterone receptor transcriptional
 1126 activity in breast cancer cells. *Biochem Biophys Res Commun* 416, 172-177.

1127 Xu, B., Bird, V.G., and Miller, W.T. (1995). Substrate specificities of the insulin and
 1128 insulin-like growth factor 1 receptor tyrosine kinase catalytic domains. *J Biol Chem*
 1129 270, 29825-29830.

1130 Yamaguchi, H., and Taouk, G.M. (2020). A Potential Role of YAP/TAZ in the
 1131 Interplay Between Metastasis and Metabolic Alterations. *Front Oncol* 10, 928.

1132 Zhao, H., Orhan, Y.C., Zha, X., Esencan, E., Chatterton, R.T., and Bulun, S.E. (2017).
 1133 AMP-activated protein kinase and energy balance in breast cancer. *Am J Transl Res* 9,
 1134 197-213.

1135

1136 **Figure Legends**

1137

1138 **Fig. 1. Targeted Antibody Array Phosphorylation data following hormone.**

1139

1140 **A)** Schematic overview of experimental procedure. Synchronised T47D cells were
 1141 exposed to hormone for the length of time indicated. Triplicate samples were harvested
 1142 and phosphorylated proteins were identified using an antibody microarray (see
 1143 materials and methods). Data was log₂ normalised resulting in a total of 246 significant
 1144 phosphosites from 155 unique proteins. **B)** Number of regulated sites per time point,

log₂FC (Fold change) >0.6<-0.6 versus time 0. **C)** Breakdown of up (>0.6log₂FC) and down (<-0.6 log₂ FC) per time point versus T0. **D)** Functional classification of the proteins identified as significantly phosphorylated across all time points, individual time point functional analysis (per time point see Fig. S2C). **E)** Venn diagram showing the overlap of significantly regulated phosphorylation sites across all time points. **F)** Log₂ FC following hormone of phosphorylated Mnk1 (T197/202) and EIF4E S209. **G)** Expression of EIF4E in normal versus breast tumour samples from breast cancer patients (Protein Atlas, see materials and methods). **H)** Kaplan Meyer overall survival stratifying patients based on the expression level of EIF4E in breast cancer data set (p=5.3e-10). **I)** mRNA expression level of EIF4E in T47D cells treated with hormone. Dynamics of **(J)** p27/KIP T187 **(K)** CDK2 T160, ERK Y202/204. **L).** Expression level of total PR and CDK2 and phospho-CDK2 T160 in T47D breast cancer cells exposed to hormone in the presence or absence of ERK inhibitor (ERKii) as determined by western blotting using specific antibodies. **(M)** CDK2 T14/Y15 phosphorylation in response to hormone as determined by antibody array. Dynamics of **(N)** Cdc25C S216 and **(O)** MAPKAPK2 T222 phosphorylation in response to hormone as determined by antibody array. **P).** Model for CDK2/ERK dynamic activation and deactivation in response to hormone based on the data presented in Fig. 1J-O.

Fig. 2. Phosphosite enriched Shotgun Proteomics following hormone.

A) T47D cells were treated with hormone at the times indicated. Biological triplicates were enriched for phosphopeptides using TiO₂ followed by LC-MS-MS peptide identification. Data was log₂ normalised resulting in a total of 310 phosphosites from 264 unique proteins. **B)** Volcano plots showing phosphopeptide log₂FC versus p-value

for each of the time points following hormone. **C)** Number of significant phosphosites identified per time point. **D)** Analysis of the proportion of threonine, tyrosine and serine phosphorylated residues identified. **E)** Breakdown of up ($>0.6\log_2\text{FC}$) and down ($<-0.6\log_2\text{FC}$) per time point versus T0. **F)** Venn diagram showing the overlap of significantly regulated phosphorylation sites over time. **G)** Phosphorylation of progesterone receptor PR (S162), following progesterone validated by western blotting in presence or absence of CDK2 inhibitor **(H)**. Total PR levels are shown as a loading control.

Fig. 3. Combining Target Antibody Arrays and Shotgun Phosphoproteomic datasets following hormone

A) KEGG pathway enrichment analysis of proteins identified as regulated by phosphorylation in response to hormone. **B)** Cellular component analysis of phosphosites enriched per time point. Showing the hormone induced phosphorylation of the nucleoplasm and cytosol across all time points (group I) the activation of membrane raft proteins enriched at 1 minute (Group II) and phosphorylation of mitochondrial proteins enriched at 15 minutes (Group III), activation of nuclear structures; PML bodies and the nuclear matrix at 60 minutes (Group IV) and the activation of the cell-cell junctions and microtubules at 360 minutes (Group V). **C)** K mean clustering of all significantly regulated phosphorylation sites over time reveals 6 distinct clusters. **D)** Similarity matrix of clusters 1-6 reveals similar dynamics for clusters 1 and 4 and an opposing similarity in phosphorylation dynamics for clusters 3 and 6. Red indicates highly similar, well correlated, blue inversely correlated patterns of regulation. **E)** Word cloud showing the enrichment of GO-biological processes

associated with proteins identified in similar clusters 1 and 4 “Early risers” which are regulated rapidly after hormone. **F)** Graph showing the opposing phosphorylation dynamic of proteins within clusters 3 and 6. **G)** Venn diagram showing the overlap of significantly identified Corum protein complexes identified in clusters 3 and 6. **H)** Phosphorylation dynamic in response to hormone of Myc S373, and T58 and BAF53 S233. **I)** Expression level of BAF53 in tumour versus normal tissue within the TGCA dataset. **J)** Phosphorylation of AMPL T183 decreases rapidly in response to hormone. **K)** Model showing the key role of AMPK dephosphorylation in response to hormone in breast cancer cells, AMPK dephosphorylation is required in order for subsequent signaling cascades including NFkB, insulin, Hippo, JAK/STAT and mTOR to continue and the phosphorylation of PR S294 to take place.

Fig. 4. Protein Complex analysis and Overlap of PARylation and Phosphorylation in response to Progesterone.

Heatmaps showing the phosphorylation of proteins within the Sam68-p85 IRS (**A**) and NF-kappa B (**B**) signalling complexes in response to hormone over time. **C)** Heatmap showing the phosphorylation of proteins of the p130 Cas-ER-Src-PI3K complex in response to hormone over time, the coordinated phosphorylation of each phosphosite individually is represented as a line graph (right panel). **D)** Venn diagram showing the overlap of proteins which contain either a phosphorylation site (379), PARylation site (1187) or both PTMs within the same protein after hormone exposure in breast cancer

cells (52). **E)** Word cloud representation showing the GO-cellular component enrichment analysis of the 52 proteins identified as phosphorylated and PARylated in response to hormone (Fig. 4D). **F)** Heatmap showing the phosphorylation of components of the KRS1-RAF1-MEK signalling complex in response to hormone over time, all proteins shown are phosphorylated and PARylated and the dynamics of individual sites is shown on the right panel. **G)** Heatmap showing the phosphorylation proteins of the Emerin complex in response to hormone over time. **H)** Heatmap showing the phosphorylation of proteins (5/15) within the Kinase Maturation complex in response to hormone over time, phosphorylation dynamics of individual sites is shown (lower panel). **I)** Venn diagram showing the phosphorylation and or PARylation of proteins contained within the kinase maturation complex; 14/15 protein components of the complex contain at least one of the PTMs. **J)** Schematic representation of the complex components, PARylated proteins are indicated by blue circle, Phosphorylated by red (right panel).

Fig. 5. Combining PPI networks from distinct cellular compartments reveals a coordinated crosstalk.

A) PPI network showing the significantly regulated phosphorylated proteins located in cell adhesion (blue) and the membrane raft (red) identified in response to hormone. **B)** Merge of the cell adhesion network (Fig. 5A, blue) and membrane raft network (Fig. 5A red). The two networks connect based on known PPI however no protein was identified as annotated in both sets. This integration of the two networks is highlighted (right panel) where proteins from each network were selected based on having a first neighbour with a protein of the other network. **C)** Violin plot showing the average

phosphorylation of proteins over time in response to hormone within the membrane raft or cell adhesion networks. Data is normalised to time 0=1. **D)** Merge of Cell Adhesion-Membrane (Fig. 6B) and the cytoskeleton networks. The two networks are merged based on known PPI. Proteins annotated in more than one function are coloured based on the Venn diagram (i.e. cytoskeleton and cell Adhesion; light green, membrane raft and cytoskeleton; brown). **E)** Heatmap showing the average phosphorylation of all proteins within each network in response to hormone over time, showing the activation of the membrane raft first at 1 minute followed by the cytoskeleton and cell adhesion.

Fig. 6. Network Integration of signalling networks identified in response to hormone.

A) PPI network showing the phosphorylated proteins present within the ERK signalling cascade (green) and the MAPK cascade (blue) identified in response to hormone. **B)** Merge of ERK-MAPK networks (Fig. 6A). The two networks are merged based on known PPI. Proteins annotated in both pathways are coloured based on the Venn diagram (fuchsia). **C)** PPI network showing the phosphorylated proteins present within the FC-receptor (yellow) and TRK-neurotrophin (red) signalling pathways (yellow) identified in response to hormone (left and middle panel). **D)** Merge of FC-receptor and TRK neurotrophin networks. The two networks are merged based on known PPI. Proteins annotated in both pathways are coloured based on the Venn diagram (orange). **E)** Rapid and coordinated phosphorylation of FOXO1 S256 and FOXO S319 in response to hormone. Kaplan Meyer overall survival of patients stratified based on the expression of NTRK2 **(F)** and FOXO1 **(G)** in breast cancer patients ($p=9.4E-10$ and

6.8e-12 respectively). All networks, PPIs and integrated cascades are supplied in Cytoscape session 2.

Supplementary Figure Legends

Fig. S1. Prior Knowledge Network (PKN) Progesterone Signalling.

A) Edge directed PKN network was manually curated from the literature. Annotated phosphorylation events, interactions, dissociations and cellular compartment are indicated. Network is available as a cytoscape network session (cys) or interaction (sys) file containing references for all edges present as shown in B) (See Supplementary File Network 1).

Fig. S2. Antibody Array controls and data analysis.

A) Schematic indicating the experimental procedure, quality control checks, and filtering applied to the antibody array experiments. **B)** Number of phosphosites identified per protein. Tau, PTK2, RPS6KA1 and RB1 are highlighted as they have multiple sites identified. **C)** Functional classification of the proteins identified as significantly phosphorylated at each time point **D)** KEGG pathway analysis, showing significant pathways ($-\log_{10}$ p-value) at each time point. **E)** Heatmap representation of GO biological process data, showing significant ($-\log_{10}$ p-value) processes at each time point. **F)** Heatmap representation of GO molecular function data, showing significant ($-\log_{10}$ p-value) functions at each time point.

Fig. S3. Phosphoproteomic data acquisition and controls.

A) Correlation of triplicate samples from each of the time points. **B)** Number of phosphosites identified per protein, the proteins showing multiple sites per protein are highlighted. **C)** KEGG pathway analysis, showing significant pathways ($-\log_{10}$ p-value) at each time point. **D)** Heatmap representation of GO-biological process data, showing significant ($-\log_{10}$ p-value) processes at each time point. **E)** Heatmap representation of GO-molecular function data, showing significant ($-\log_{10}$ p-value) functions per time point.

Fig S4. Combining Antibody Array and Phosphoproteomic LC-MS-MS datasets.

A) Schematic representation showing the methodology and overlap combining antibody array and LC-MS-MS datasets. **B)** PCA analysis of phosphorylation datasets. **C)** Number of phosphosites identified per protein, the names of proteins showing multiple sites per protein are highlighted. **D)** Venn diagram showing the overlap of phosphosites per time point. **E)** Up and down regulated phosphorylation sites identified per time point. **F)** Phosphorylation levels of the proteins identified as significantly regulated after hormone located within the mitochondria. **G)** Analysis of the number of functions to which each unique protein was assigned **H)** Venn diagram showing the overlap of protein functional class; Enzymes, Structural protein, Membrane-cell-cell contact, protein modulators and proteins with nucleic acid binding capacities.

Fig S5. Functional Analysis of Proteins Identified.

All proteins were assigned one or more function based on GSEA database. Both Parent (outside/title), and children (within) are shown for each class and the proteins identified within that sub-group are shown. Nucleic acid binding (**A**), Membrane/Cell-cell contact (**B**), Protein Modulators (**C**), Enzymes (**D**), Cell signalling (**E**), and Structural proteins (**F**).

Fig S6. Gene Ontology and Pathway analysis of combined dataset.

A) Heatmap representation of GO biological process data, showing significant ($-\log_{10}$ p-value) biological processes enrichment based on the protein phosphorylation at each time point. **B)** Heatmap representation of GO molecular function enrichment, showing significant ($-\log_{10}$ p-value) functions at each time point following hormone. **C)** KEGG pathway analysis, showing significant pathways ($-\log_{10}$ p-value) enriched at each time point following hormone exposure. **D)** Protein protein interaction (PPI) network generated using proteins identified as phosphorylated following hormone and were assigned as cytoskeleton located.

Fig S7. Pathway Network Generation in Breast Cancer cells in response to Hormone.

A) Protein protein interaction (PPI) network was generated using full phosphorylation dataset encompassing 321 proteins (Supplementary Material Network session 2) in Cytoscape using GenemaniaTM only considering protein-protein interactions with experimental evidence (Supp. Materials and methods), each node represents and

individual protein and interactions are represented by edges. Functional analysis was carried out to identify key pathways enriched within the full network (Full list Supplementary Table 16). Individual networks were generated from each function individually and are available within additional Network session 2. Graphs of several pathways determined to be enriched within the dataset are shown **B)** Fc receptor, **C)** MAPK, **D)** EGF **E)** ERK **F)** Insulin, **G)** TRK signalling, **H)** ERBB.

Supplementary Table Legends

Supplementary Table S1

Uniprot IDs of phosphorylated proteins identified in response to hormone. Time after hormone (minutes), data is normalized 0-1 row maximum and minimum.

Supplementary Table S2

KEGG pathway enrichment; the pathway term, p value and the proteins associated with the pathway are shown.

Supplementary Table S3

Cellular component enrichment analysis of phosphorylated proteins. The time after hormone in which they peak, the adjusted p value, and proteins associated with each specific cellular component are given.

Supplementary Table S4

Gene Ontology Biological Process enrichment analysis of phosphorylated proteins. The cluster in which the term is enriched, the adjusted p value, and proteins associated with each specific biological process are given.

Supplementary Table S5

Gene Ontology Molecular Function enrichment analysis of phosphorylated proteins. The cluster in which the term is enriched, the adjusted p value, and proteins associated with each specific molecular function are given.

Supplementary Table S6

Corum enrichment analysis of phosphorylated proteins. The p-value, and proteins associated with each complex are given.

Supplementary Table S7

Cellular component enrichment analysis of phosphorylated and PARylated proteins. The adjusted p value, and proteins associated with each specific cellular component are given.

Supplementary Table S8

Corum enrichment analysis of phosphorylated and PARylated proteins. The p-value, and proteins associated with each complex are given, phosphorylated proteins are highlighted in yellow.

Supplementary Table S9

Genemania analysis of phosphorylated proteins, all protein IDs are listed along with the GO: IDs for which they are associated.

Supplementary Table S10

Genemania analysis of phosphorylated proteins, the pathways enriched in Network 2 are shown. The q value and the number of occurrences in the network versus the occurrences in the Network are shown.

Additional Files

Network Session 1

Edge directed PKN network was manually curated from the literature. Annotated phosphorylation events, interactions, dissociations and cellular compartment are indicated.

Network Session 2

1419 Protein protein interaction (PPI) network was generated using full phosphorylation
1420 dataset encompassing 321 proteins in Cytoscape using GenemaniaTM only considering
1421 protein-protein interactions with experimental evidence each node represents and
1422 individual protein and interactions are represented by edges. Functional analysis was
1423 carried out to identify key pathways enriched within the full network. Individual
1424 networks were generated from each function individually and are available as unique
1425 networks within Network session.
1426
1427

Figures

Figure 1

Targeted Antibody Array Phosphorylation data following hormone. A) Schematic overview of experimental procedure. Synchronised T47D cells were exposed to hormone for the length of time indicated. Triplicate samples were harvested and phosphorylated proteins were identified using an

antibody microarray (see materials and methods). Data was log2 normalised resulting in a total of 246 significant phosphosites from 155 unique proteins. B) Number of regulated sites per time point, log2FC (Fold change) >0.6 <-0.6 versus time 0. C) Breakdown of up (>0.6 log2FC) and down (<-0.6 log2 FC) per time point versus T0. D) Functional classification of the proteins identified as significantly phosphorylated across all time points, individual time point functional analysis (per time point see Fig. S2C). E) Venn diagram showing the overlap of significantly regulated phosphorylation sites across all time points. F) Log2 FC following hormone of phosphorylated Mnk1 (T197/202) and EIF4E S209. G) Expression of EIF4E in normal versus breast tumour samples from breast cancer patients (Protein Atlas, see materials and methods). H) Kaplan Meyer overall survival stratifying patients based on the expression level of EIF4E in breast cancer data set 1154 ($p=5.3e-10$). I) mRNA expression level of EIF4E in T47D cells treated with hormone. Dynamics of (J) p27/KIP T187 (K) CDK2 T160, ERK Y202/204. L). Expression level 1156 of total PR and CDK2 and phospho-CDK2 T160 in T47D breast cancer cells exposed to hormone in the presence or absence of ERK inhibitor (ERKii) as determined by western blotting using specific antibodies. (M) CDK2 T14/Y15 phosphorylation in response to hormone as determined by antibody array. Dynamics of (N) Cdc25C S216 1160 and (O) MAPKAPK2 T222 phosphorylation in response to hormone as determined by 1161 antibody array. P). Model for CDK2/ERK dynamic activation and deactivation in response to hormone based on the data presented in Fig. 1J-O

Fig. 2

Figure 2

Phosphosite enriched Shotgun Proteomics following hormone. A) T47D cells were treated with hormone at the times indicated. Biological triplicates were enriched for phosphopeptides using TiO2 followed by LC-MS-MS peptide identification. Data was log2 normalised resulting in a total of 310 phosphosites from 264 unique proteins. B) Volcano plots showing phosphopeptide log2FC versus p-value for each of the time points following hormone. C) Number of significant phosphosites identified per time point. D)

Fig. 3

Combining Target Antibody Arrays and Shotgun Phosphoproteomic datasets following hormone A) KEGG pathway enrichment analysis of proteins identified as regulated by phosphorylation in response to hormone. B) Cellular component analysis of phosphosites enriched per time point. Showing the hormone induced phosphorylation of the nucleoplasm and cytosol across all time points (group I) the activation of membrane raft proteins enriched at 1 minute (Group II) and phosphorylation of mitochondrial proteins enriched at 15 minutes (Group III), activation of nuclear structures; PML bodies and the nuclear matrix at 60 minutes (Group IV) and the activation of the cell-cell junctions and microtubules at 360 minutes (Group V). C) K mean clustering of all significantly regulated phosphorylation sites over time reveals 6 distinct clusters. D) Similarity matrix of clusters 1-6 reveals similar dynamics for clusters 1 and 4 and an opposing similarity in phosphorylation dynamics for clusters 3 and 6. Red indicates highly similar, well correlated, blue inversely correlated patterns of regulation. E) Word cloud showing the enrichment of GO-biological processes associated with proteins identified in similar clusters 1 and 4 “Early risers” which are regulated rapidly after hormone. F) Graph showing the opposing phosphorylation dynamic of proteins within clusters 3 and 6. G) Venn diagram showing the overlap of significantly identified Corum protein complexes identified in clusters 3 and 6. H) Phosphorylation dynamic in response to hormone of Myc S373, and T58 and BAF53 S233. I) Expression level of BAF53 in tumour versus normal tissue within the TGCA dataset. J) Phosphorylation of AMPL T183 decreases rapidly in response to hormone. K) Model showing the key role of AMPK dephosphorylation in response to hormone in breast cancer cells, AMPK dephosphorylation is required in order for subsequent signaling cascades including NFkB, insulin, Hippo, JAK/STAT and mTOR to continue and the phosphorylation of PR S294 to take place.

diagram showing the overlap of proteins which contain either a phosphorylation site (379), PARylation site (1187) or both PTMs within the same protein after hormone exposure in breast cancer cells (52). E) Word cloud representation showing the GO-cellular component enrichment analysis of the 52 proteins identified as phosphorylated and PARylated in response to hormone (Fig. 4D). F) Heatmap showing the phosphorylation of components of the KRS1-RAF1-MEK signalling complex in response to hormone over time, all proteins shown are phosphorylated and PARylated and the dynamics of individual sites is shown on the right panel. G) Heatmap showing the phosphorylation proteins of the Emerin complex in response to hormone over time. H) Heatmap showing the phosphorylation of proteins (5/15) within the Kinase Maturation complex in response to hormone over time, phosphorylation dynamics of individual sites is shown (lower panel). I) Venn diagram showing the phosphorylation and or PARylation of proteins contained within the kinase maturation complex; 14/15 protein components of the complex contain at least one of the PTMs. J) Schematic representation of the complex components, PARylated proteins are indicated by blue circle, Phosphorylated by red (right panel)

Fig. 5

Figure 5

Combining PPI networks from distinct cellular compartments reveals a coordinated crosstalk. A) PPI network showing the significantly regulated phosphorylated proteins located in cell adhesion (blue) and the membrane raft (red) identified in response to hormone. B) Merge of the cell adhesion network (Fig. 5A, blue) and membrane raft network (Fig. 5A red). The two networks connect based on known PPI however no protein was identified as annotated in both sets. This integration of the two networks is highlighted

(right panel) where proteins from each network were selected based on having a first neighbour with a protein of the other network. C) Violin plot showing the average phosphorylation of proteins over time in response to hormone within the membrane raft or cell adhesion networks. Data is normalised to time 0=1. D) Merge of Cell Adhesion Membrane (Fig. 6B) and the cytoskeleton networks. The two networks are merged based on known PPI. Proteins annotated in more than one function are coloured based on the Venn diagram (i.e. cytoskeleton and cell Adhesion; light green, membrane raft and cytoskeleton; brown). E) Heatmap showing the average phosphorylation of all proteins within each network in response to hormone over time, showing the activation of the membrane raft first at 1 minute followed by the cytoskeleton and cell adhesion.

Fig. 6

Figure 6

Network Integration of signalling networks identified in response to hormone. A) PPI network showing the phosphorylated proteins present within the ERK signalling cascade (green) and the MAPK cascade (blue) identified in response to hormone. B) Merge of ERK-MAPK networks (Fig. 6A). The two networks are merged based on known PPI. Proteins annotated in both pathways are coloured based on the Venn diagram (fuchsia). C) PPI network showing the phosphorylated proteins present within the FC-receptor

(yellow) and TRK-neurotrophin (red) signalling pathways (yellow) identified in response to hormone (left and middle panel). D) Merge of FC-receptor and TRK neurotrophin networks. The two networks are merged based on known PPI. Proteins annotated in both pathways are coloured based on the Venn diagram (orange). E) Rapid and coordinated phosphorylation of FOXO1 S256 and FOXO S319 in 1267 response to hormone. Kaplan Meyer overall survival of patients stratified based on the expression of NTRK2 (F) and FOXO1 (G) in breast cancer patients ($p=9.4E-10$ and $6.8e-12$ respectively). All networks, PPIs and integrated cascades are supplied in Cytoscape session 2.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SuppTable7.xlsx](#)
- [SuppTables1and2.xlsx](#)
- [SuppTables3and4.xlsx](#)
- [SuppTables810.xlsx](#)
- [Supptable5and6.xlsx](#)
- [SupplementaryFigures1to3.pdf](#)
- [SupplementaryFigures4to7.pdf](#)